
Wayne D Hall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8130821/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
2	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
3	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
4	Grand challenges in global mental health. Nature, 2011, 475, 27-30.	27.8	1,654
5	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet, The, 2012, 379, 55-70.	13.7	1,074
6	Adverse health effects of non-medical cannabis use. Lancet, The, 2009, 374, 1383-1391.	13.7	941
7	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry,the, 2018, 5, 987-1012.	7.4	885
8	Prevalence, comorbidity, disability and service utilisation. British Journal of Psychiatry, 2001, 178, 145-153.	2.8	847
9	Cannabis use and mental health in young people: cohort study. BMJ: British Medical Journal, 2002, 325, 1195-1198.	2.3	809
10	The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 1995, 90, 607-614.	3.3	762
11	Adverse effects of cannabis. Lancet, The, 1998, 352, 1611-1616.	13.7	719
12	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018, 113, 1905-1926.	3.3	685
13	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet, The, 2013, 382, 1564-1574.	13.7	668
14	Development of a short â€~readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Addiction, 1992, 87, 743-754.	3.3	665
15	Exploring the association between cannabis use and depression. Addiction, 2003, 98, 1493-1504.	3.3	470
16	The effects of adolescent cannabis use on educational attainment: a review. Addiction, 2000, 95, 1621-1630.	3.3	459
17	The AUDIT questionnaire: choosing a cut-off score. Addiction, 1995, 90, 1349-1356.	3.3	444
18	What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?. Addiction, 2015, 110, 19-35.	3.3	440

#	Article	IF	CITATIONS
19	Role of maintenance treatment in opioid dependence. Lancet, The, 1999, 353, 221-226.	13.7	399
20	Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Addiction, 1992, 87, 733-742.	3.3	381
21	The increasing global health priority of substance use in young people. Lancet Psychiatry,the, 2016, 3, 251-264.	7.4	378
22	Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry,the, 2014, 1, 286-293.	7.4	354
23	Fortnightly Review: Methadone maintenance treatment in opiate dependence: a review. BMJ: British Medical Journal, 1994, 309, 997-1001.	2.3	345
24	Recreational MDMA use in Sydney: a profile of †̃Ecstasy' users and their experiences with the drug. Addiction, 1992, 87, 1161-1172.	3.3	340
25	Heroin overdose: causes and consequences. Addiction, 2001, 96, 1113-1125.	3.3	335
26	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 2018, 159, 1932-1954.	4.2	321
27	Australia's Mental Health: An Overview of the General Population Survey. Australian and New Zealand Journal of Psychiatry, 2000, 34, 197-205.	2.3	317
28	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 2009, 105, 9-15.	3.2	309
29	The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction, 2014, 109, 1320-1333.	3.3	308
30	Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry,the, 2019, 6, 995-1010.	7.4	306
31	Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry,the, 2016, 3, 280-296.	7.4	296
32	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, e1-e12.	2.7	295
33	The adverse health effects of chronic cannabis use. Drug Testing and Analysis, 2014, 6, 39-45.	2.6	288
34	Heroin Overdose: Research and Evidence-Based Intervention. Journal of Urban Health, 2003, 80, 189-200.	3.6	280
35	Alcohol use disorders. Lancet, The, 2016, 387, 988-998.	13.7	277
36	Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction, 2016, 111, 1764-1773.	3.3	270

#	Article	IF	CITATIONS
37	Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 2001, 96, 1603-1614.	3.3	263
38	Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ: British Medical Journal, 2003, 326, 1008-1008.	2.3	263
39	Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction, 1996, 91, 405-411.	3.3	260
40	Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence, 2003, 71, 37-48.	3.2	242
41	Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction, 1996, 91, 405-411.	3.3	241
42	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PLoS ONE, 2013, 8, e76635.	2.5	235
43	The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. Aids, 1991, 5, 181-186.	2.2	234
44	Why young people's substance use matters for global health. Lancet Psychiatry,the, 2016, 3, 265-279.	7.4	230
45	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet, The, 2019, 394, 1580-1590.	13.7	224
46	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infectious Diseases, The, 2016, 16, 1385-1398.	9.1	223
47	Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug and Alcohol Review, 2005, 24, 39-48.	2.1	217
48	Mitigating and learning from the impact of COVIDâ€19 infection on addictive disorders. Addiction, 2020, 115, 1007-1010.	3.3	204
49	Prevalence and correlates of DSMâ€ŀV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction, 2010, 105, 2085-2094.	3.3	203
50	The AUDIT questionnaire: choosing a cut-off score. Addiction, 2006, 90, 1349-1356.	3.3	200
51	Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. Water Research, 2011, 45, 4437-4448.	11.3	196
52	New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet, The, 2019, 394, 1668-1684.	13.7	195
53	Alcohol- and Drug-Use Disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	193
54	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction, 2013, 108, 124-133.	3.3	183

#	Article	IF	CITATIONS
55	Mortality among cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence, 2011, 113, 88-95.	3.2	182
56	Are detoxification programmes effective?. Lancet, The, 1996, 347, 97-100.	13.7	181
57	Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 2021, 7, 16.	30.5	179
58	The alcohol withdrawal syndrome. Lancet, The, 1997, 349, 1897-1900.	13.7	177
59	Long-term cannabis use: characteristics of users in an Australian rural area. Addiction, 1998, 93, 837-846.	3.3	176
60	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health, The, 2018, 3, e341-e350.	10.0	172
61	A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence, 2003, 72, 59-65.	3.2	169
62	The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine, 2001, 31, 659-668.	4.5	167
63	Obesity, Alcohol Consumption and Blood Pressure in Australian Men and Women The National Heart Foundation of Australia Risk Factor Prevalence Study. Journal of Hypertension, 1984, 2, 85-91.	0.5	165
64	Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug and Alcohol Dependence, 1995, 39, 231-235.	3.2	164
65	Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence. Australian and New Zealand Journal of Psychiatry, 2000, 34, 26-34.	2.3	160
66	The adverse health effects of cannabis use: What are they, and what are their implications for policy?. International Journal of Drug Policy, 2009, 20, 458-466.	3.3	160
67	Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry, 2020, 19, 179-186.	10.4	159
68	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. Lancet Psychiatry,the, 2015, 2, 105-110.	7.4	158
69	Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction, 2007, 102, 607-615.	3.3	152
70	The Neurobiology of "Food Addiction―and Its Implications for Obesity Treatment and Policy. Annual Review of Nutrition, 2016, 36, 105-128.	10.1	151
71	Smart Drugs "As Common As Coffee†Media Hype about Neuroenhancement. PLoS ONE, 2011, 6, e28416.	2.5	149
72	The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction, 1999, 94, 1541-1550.	3.3	145

#	Article	IF	CITATIONS
73	Estimating treatment rates for mental disorders in Australia. Australian Health Review, 2014, 38, 80.	1.1	145
74	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug and Alcohol Dependence, 2017, 179, 291-298.	3.2	142
75	Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug and Alcohol Review, 2010, 29, 318-330.	2.1	141
76	Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clinical Pharmacology and Therapeutics, 2015, 97, 607-615.	4.7	141
77	The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence, 2001, 64, 319-327.	3.2	140
78	Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry, 2007, 20, 393-397.	6.3	139
79	Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 741-753.	1.9	138
80	Heroin overdose: the case for take-home naloxone. BMJ: British Medical Journal, 1996, 312, 1435-1436.	2.3	138
81	Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet, The, 2007, 369, 2010-2014.	13.7	135
82	Calculating standard drink units: international comparisons. Addiction, 1991, 86, 43-47.	3.3	133
83	How many dependent heroin users are there in Australia?. Medical Journal of Australia, 2000, 173, 528-531.	1.7	133
84	Choosing a diagnostic cutâ€off for cannabis dependence. Addiction, 1998, 93, 1681-1692.	3.3	132
85	A longitudinal study of the association of adolescent polydrug use, alcohol use and high school non ompletion. Addiction, 2015, 110, 627-635.	3.3	130
86	Alcohol- and drug-use disorders in Australia: implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	128
87	The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drug and Alcohol Dependence, 2014, 137, 36-47.	3.2	126
88	Crystalline methamphetamine use and methamphetamineâ€related harms in Australia. Drug and Alcohol Review, 2017, 36, 160-170.	2.1	126
89	Cannabis use and psychosis: a review of reviews. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 403-412.	3.2	123
90	Effects of a sustained heroin shortage in three Australian States. Addiction, 2005, 100, 908-920.	3.3	121

#	Article	IF	CITATIONS
91	Systematic Review of Interventions to Improve Prescribing. Annals of Pharmacotherapy, 2009, 43, 502-513.	1.9	121
92	The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Social Psychiatry and Psychiatric Epidemiology, 2001, 36, 219-227.	3.1	120
93	What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addictive Behaviors, 2020, 109, 106479.	3.0	120
94	Substance use and the adolescent brain: A toxic combination?. Journal of Psychopharmacology, 2007, 21, 792-794.	4.0	116
95	The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports, 2018, 18, 8.	4.2	116
96	Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ: British Medical Journal, 2010, 341, c4851-c4851.	2.3	114
97	What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug and Alcohol Dependence, 2011, 117, 85-101.	3.2	114
98	The long-term effectiveness of brief interventions for unsafe alcohol consumption: a 10-year follow-up. Addiction, 2002, 97, 665-675.	3.3	111
99	Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction, 2001, 96, 737-748.	3.3	109
100	Cannabis use and the risk of developing a psychotic disorder. World Psychiatry, 2008, 7, 68-71.	10.4	109
101	Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence, 1999, 54, 155-161.	3.2	108
102	Gateway or common liability? A systematic review and metaâ€analysis of studies of adolescent e igarette use and future smoking initiation. Addiction, 2021, 116, 743-756.	3.3	108
103	What are the policy lessons of National Alcohol Prohibition in the United States, 1920–1933?. Addiction, 2010, 105, 1164-1173.	3.3	106
104	Systematic review of prospective studies investigating "remission―from amphetamine, cannabis, cocaine or opioid dependence. Addictive Behaviors, 2010, 35, 741-749.	3.0	106
105	Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health, 2000, 24, 421-426.	1.8	105
106	Evaluating explanations of the Australian â€~heroin shortage'. Addiction, 2005, 100, 459-469.	3.3	105
107	Is Cannabis Use a Contributory Cause of Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 556-565.	1.9	105
108	Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction, 1996, 91, 413-417.	3.3	105

#	Article	IF	CITATIONS
109	The Pain and Opioids IN Treatment study. Pain, 2015, 156, 231-242.	4.2	104
110	Social, demographic, and economic correlates of food and chemical consumption measured by wastewater-based epidemiology. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21864-21873.	7.1	104
111	Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival. Drug and Alcohol Review, 2013, 32, 594-602.	2.1	103
112	Mobile Phones in Research and Treatment: Ethical Guidelines and Future Directions. JMIR MHealth and UHealth, 2015, 3, e95.	3.7	103
113	Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug and Alcohol Dependence, 1993, 34, 67-70.	3.2	102
114	Trends in opiate overdose deaths in Australia 1979–1995. Drug and Alcohol Dependence, 1998, 52, 71-77.	3.2	102
115	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 2015, 16, 356-366.	1.9	102
116	Attention Deficit Hyperactivity Disorder and substance use disorders: is there a causal link?. Addiction, 2001, 96, 815-822.	3.3	101
117	Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semiâ€rural and a vacation area. Addiction, 2013, 108, 556-565.	3.3	101
118	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 2015, 147, 144-150.	3.2	97
119	The distribution of naloxone to heroin users. Addiction, 1997, 92, 1195-1200.	3.3	93
120	The genetics of tobacco use: methods, findings and policy implications. Tobacco Control, 2002, 11, 119-124.	3.2	93
121	Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence, 2009, 105, 1-8.	3.2	93
122	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction, 2014, 109, 90-99.	3.3	92
123	Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. International Journal of Drug Policy, 2020, 77, 102698.	3.3	91
124	Should the Health Community Promote Smokeless Tobacco (Snus) as a Harm Reduction Measure?. PLoS Medicine, 2007, 4, e185.	8.4	90
125	Establishing and Governing e-Mental Health Care in Australia: A Systematic Review of Challenges and A Call For Policy-Focussed Research. Journal of Medical Internet Research, 2016, 18, e10.	4.3	89
126	Cannabis use and psychotic disorders: an update. Drug and Alcohol Review, 2004, 23, 433-443.	2.1	88

#	Article	IF	CITATIONS
127	Quantification of physical illness in psychiatric research in the elderly. International Journal of Geriatric Psychiatry, 1990, 5, 161-170.	2.7	87
128	A systematic review of research examining benzodiazepineâ€related mortality. Pharmacoepidemiology and Drug Safety, 2009, 18, 93-103.	1.9	87
129	Transitions between routes of administration of regular amphetamine users. Addiction, 1994, 89, 1077-1083.	3.3	86
130	Trends in opiate-related deaths in the United Kingdom and Australia, 1985–1995. Drug and Alcohol Dependence, 2000, 57, 247-254.	3.2	86
131	MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet, The, 2000, 355, 1818-1821.	13.7	86
132	A comparison of a specialist women's alcohol and other drug treatment service with two traditional mixed-sex services: client characteristics and treatment outcome. Drug and Alcohol Dependence, 1993, 32, 81-92.	3.2	84
133	Spatial variations in the consumption of illicit stimulant drugs across Australia: A nationwide application of wastewater-based epidemiology. Science of the Total Environment, 2016, 568, 810-818.	8.0	84
134	A comparison of women seeking drug and alcohol treatment in a specialist women's and two traditional mixed-sex treatment services. Addiction, 1992, 87, 1293-1302.	3.3	83
135	Cannabis use and the Mental Health of Young People. Australian and New Zealand Journal of Psychiatry, 2006, 40, 105-113.	2.3	83
136	Patterns of Antipsychotic Medication Use in Australia 2002–2007. Australian and New Zealand Journal of Psychiatry, 2010, 44, 372-377.	2.3	83
137	An evaluation of a project-based learning initiative in engineering education. European Journal of Engineering Education, 2011, 36, 357-365.	2.3	83
138	Heroin-assisted treatment as a response to the public health problem of opiate dependence. European Journal of Public Health, 2002, 12, 228-234.	0.3	82
139	Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 2001, 96, 1289-1296.	3.3	81
140	Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections, 2006, 82, iii56-iii63.	1.9	81
141	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction, 2009, 104, 1363-1372.	3.3	81
142	Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. European Neuropsychopharmacology, 2020, 36, 169-180.	0.7	81
143	Crime and drug use among applicants for methadone maintenance. Drug and Alcohol Dependence, 1993, 31, 123-129.	3.2	79
144	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine, 2007, 37, 927-934.	4.5	79

#	Article	lF	CITATIONS
145	Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction, 2011, 106, 283-293.	3.3	79
146	Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction, 1996, 91, 81-87.	3.3	79
147	Estimating drug consumption in opioid users: reliability and validity of aâ€~recent use' episodes method. British Journal of Addiction, 1991, 86, 1311-1316.	0.1	78
148	Benzodiazepine use among injecting heroin users. Medical Journal of Australia, 1995, 162, 645-647.	1.7	78
149	An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. Addiction, 2012, 107, 1767-1773.	3.3	78
150	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 2015, 16, 1745-1758.	1.9	78
151	Estimating the number of regular and dependent methamphetamine users in Australia, 2002–2014. Medical Journal of Australia, 2016, 204, 153-153.	1.7	78
152	Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug and Alcohol Dependence, 1992, 31, 31-36.	3.2	77
153	Cannabis use and psychosis. Drug and Alcohol Review, 1998, 17, 433-444.	2.1	77
154	Quitting smoking: estimation by metaâ€analysis of the rate of unaided smoking cessation. Australian Journal of Public Health, 1995, 19, 129-131.	0.2	76
155	Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry, 1997, 171, 4-5.	2.8	75
156	Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review, 1998, 17, 153-158.	2.1	75
157	The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?. Drug and Alcohol Review, 2014, 33, 4-12.	2.1	75
158	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy, 2022, 99, 103381.	3.3	75
159	Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncology, The, 2005, 6, 35-42.	10.7	74
160	Changes in criminal activity after entering methadone maintenance. Addiction, 1992, 87, 251-258.	3.3	73
161	Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. Addiction, 1996, 91, 1141-1150.	3.3	73
162	Cannabis use and public health: assessing the burden. Addiction, 2000, 95, 485-490.	3.3	73

#	Article	IF	CITATIONS
163	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. Canadian Journal of Public Health, 2011, 102, 324-327.	2.3	72
164	Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence, 1997, 46, 105-113.	3.2	71
165	Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug and Alcohol Dependence, 2001, 63, 147-153.	3.2	71
166	User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate. Drug and Alcohol Dependence, 2017, 178, 32-38.	3.2	71
167	One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug and Alcohol Dependence, 2000, 59, 309-318.	3.2	70
168	Treatment rates for alcohol use disorders: a systematic review and metaâ€analysis. Addiction, 2021, 116, 2617-2634.	3.3	70
169	Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction, 1996, 91, 413-417.	3.3	69
170	Food Addiction and Its Impact on Weight-Based Stigma and the Treatment of Obese Individuals in the U.S. and Australia. Nutrients, 2014, 6, 5312-5326.	4.1	68
171	Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction, 1994, 89, 211-217.	3.3	67
172	Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology, 2006, 6, 16.	3.1	67
173	From "our world―to the "real world― Exploring the views and behaviour of policy-influential Australian public health researchers. Social Science and Medicine, 2011, 72, 1047-1055.	3.8	67
174	Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. Psychological Medicine, 2016, 46, 877-889.	4.5	67
175	Tobacco and nicotine use. Nature Reviews Disease Primers, 2022, 8, 19.	30.5	67
176	Polysubstance Use in Cannabis Users Referred for Treatment: Drug Use Profiles, Psychiatric Comorbidity and Cannabis-Related Beliefs. Frontiers in Psychiatry, 2013, 4, 79.	2.6	66
177	Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry,the, 2016, 3, 900-906.	7.4	66
178	A comparison of predictors of treatment drop-out of women seeking drug and alcohol treatment in a specialist women's and two traditional mixed-sex treatment services. Addiction, 1992, 87, 883-890.	3.3	65
179	The effectiveness of methadone maintenance treatment: an overview. Drug and Alcohol Review, 1994, 13, 327-336.	2.1	65
180	Disability, outcome and case-mix in acute psychiatric in-patient units. British Journal of Psychiatry, 1997, 171, 242-246.	2.8	65

#	ŧ	Article	IF	CITATIONS
1	.81	Opioid overdose mortality in Australia, 1964–1997: birth ohort trends. Medical Journal of Australia, 1999, 171, 34-37.	1.7	65
1	.82	Why Don't Smokers Want Help to Quit? A Qualitative Study of Smokers' Attitudes towards Assisted vs. Unassisted Quitting. International Journal of Environmental Research and Public Health, 2015, 12, 6591-6607.	2.6	65
1	.83	Systematic and Day-to-Day Effects of Chemical-Derived Population Estimates on Wastewater-Based Drug Epidemiology. Environmental Science & Technology, 2015, 49, 999-1008.	10.0	65
1	.84	Autism is not associated with the Fragile X syndrome. American Journal of Medical Genetics Part A, 1989, 34, 187-193.	2.4	64
1	.85	Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction, 1996, 91, 81-87.	3.3	64
1	.86	Methadone maintenance and drug-related crime. Journal of Substance Abuse, 1997, 9, 15-25.	1.1	64
1	.87	Cannabis and psychosis. Current Psychiatry Reports, 2002, 4, 191-196.	4.5	64
1	.88	Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Medical Journal of Australia, 2015, 203, 299-299.	1.7	63
1	.89	Drug and alcohol treatment providers' views about the disease model of addiction and its impact on clinical practice: A systematic review. Drug and Alcohol Review, 2018, 37, 697-720.	2.1	63
1	90	Life Events, Life Difficulties and Confiding Relationships in the Depressed Elderly. British Journal of Psychiatry, 1989, 155, 787-792.	2.8	62
1	.91	Deflating the Neuroenhancement Bubble. AJOB Neuroscience, 2011, 2, 38-43.	1.1	62
1	92	Sewage epidemiology and illicit drug research: The development of ethical research guidelines. Science of the Total Environment, 2014, 472, 550-555.	8.0	62
1	.93	Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewaterâ€based epidemiology. Addiction, 2018, 113, 1127-1136.	3.3	62
1	94	Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review, 2003, 22, 7-13.	2.1	61
1	.95	The persistence of adolescent binge drinking into adulthood: findings from a 15-year prospective cohort study. BMJ Open, 2013, 3, e003015.	1.9	61
1	.96	Cocaine, MDMA and methamphetamine residues in wastewater: Consumption trends (2009–2015) in South East Queensland, Australia. Science of the Total Environment, 2016, 568, 803-809.	8.0	61
1	.97	Predictors of injecting and injecting risk-taking behaviour among methadone maintenance clients. Addiction, 1994, 89, 311-316.	3.3	60
1	.98	Heroin use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the Illicit Drug Reporting System (IDRS). Addiction, 2002, 97, 179-186.	3.3	60

#	Article	IF	CITATIONS
199	Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1182-1192.	2.3	60
200	Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when?. Tobacco Control, 2009, 18, 183-189.	3.2	59
201	Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. International Journal of Drug Policy, 2010, 21, 10-19.	3.3	59
202	A National Wastewater Monitoring Program for a better understanding of public health: A case study using the Australian Census. Environment International, 2019, 122, 400-411.	10.0	59
203	Cannabis and COVID-19: Reasons for Concern. Frontiers in Psychiatry, 2020, 11, 601653.	2.6	59
204	Methadone maintenance reduces injecting in prison. BMJ: British Medical Journal, 1996, 312, 1162-1162.	2.3	59
205	Drug use, injecting practices and sexual behaviour of opioid users in Sydney, Australia. Addiction, 1990, 85, 1603-1609.	3.3	58
206	The Ethics of Paying Drug Users Who Participate in Research: A Review and Practical Recommendations. Journal of Empirical Research on Human Research Ethics, 2006, 1, 21-35.	1.3	58
207	Identifying Trustworthy Experts: How Do Policymakers Find and Assess Public Health Researchers Worth Consulting or Collaborating With?. PLoS ONE, 2012, 7, e32665.	2.5	58
208	Decreased heroin availability in Sydney in early 2001. Addiction, 2003, 98, 93-95.	3.3	57
209	Australian University Students' Attitudes Towards the Acceptability and Regulation of Pharmaceuticals to Improve Academic Performance. Neuroethics, 2013, 6, 197-205.	2.8	57
210	Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. Addiction, 2019, 114, 847-856.	3.3	57
211	Will Legalization and Commercialization of Cannabis Use Increase the Incidence and Prevalence of Psychosis?. JAMA Psychiatry, 2020, 77, 777.	11.0	57
212	The Development of an early Warning System to Detect Trends in Illicit Drug use in Australia: The Illicit Drug Reporting System. Addiction Research, 1998, 6, 97-113.	0.6	56
213	The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction, 2010, 105, 2041-2043.	3.3	56
214	<scp>A</scp> ustralian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: Perceived patterns of use, efficacy and safety. Drug and Alcohol Review, 2013, 32, 295-302.	2.1	56
215	Long-term cannabis use and mental health. British Journal of Psychiatry, 1997, 171, 107-108.	2.8	55
216	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. Lancet Psychiatry,the, 2015, 2, 314-322.	7.4	55

#	Article	IF	CITATIONS
217	Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence, 1996, 43, 191-198.	3.2	54
218	Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction, 2002, 97, 977-984.	3.3	54
219	Realising the technological promise of smartphones in addiction research and treatment: An ethical review. International Journal of Drug Policy, 2016, 36, 47-57.	3.3	54
220	How have the SSRI antidepressants affected suicide risk?. Lancet, The, 2006, 367, 1959-1962.	13.7	53
221	Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. Addictive Behaviors, 2009, 34, 526-530.	3.0	53
222	The Problem of Multiple Inference in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1985, 19, 265-274.	2.3	51
223	What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders?. Drug and Alcohol Review, 1996, 15, 157-170.	2.1	51
224	Increasing cancer mortality among opioidâ€dependent persons in Australia: a new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health, 2011, 35, 220-225.	1.8	51
225	Has the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders?. Current Addiction Reports, 2018, 5, 403-417.	3.4	51
226	Lessons from the public health responses to the US outbreak of vapingâ€related lung injury. Addiction, 2021, 116, 985-993.	3.3	51
227	Meta-analytic review of the efficacy of smoking cessation interventions. Drug and Alcohol Review, 1994, 13, 157-170.	2.1	50
228	Public Views on Food Addiction and Obesity: Implications for Policy and Treatment. PLoS ONE, 2013, 8, e74836.	2.5	50
229	Factors influencing women's decisions to drink alcohol during pregnancy: findings of a qualitative study with implications for health communication. BMC Pregnancy and Childbirth, 2014, 14, 246.	2.4	50
230	Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation. Australian and New Zealand Journal of Psychiatry, 2015, 49, 106-117.	2.3	50
231	Effect of Cytisine vs Varenicline on Smoking Cessation. JAMA - Journal of the American Medical Association, 2021, 326, 56.	7.4	50
232	A systematic review of randomized controlled trials and network meta-analysis of e-cigarettes for smoking cessation. Addictive Behaviors, 2021, 119, 106912.	3.0	50
233	Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. Drug and Alcohol Dependence, 1994, 34, 253-257.	3.2	49
234	Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction, 1998, 93, 1149-1160.	3.3	49

#	Article	IF	CITATIONS
235	Prevalence of illicit drug use among youth: results from the Australian School Students' Alcohol and Drugs Survey. Australian and New Zealand Journal of Public Health, 1999, 23, 519-524.	1.8	49
236	Feeling â€~better than well'. EMBO Reports, 2004, 5, 1105-1109.	4.5	49
237	Epidemiology of alcoholâ€related burden of disease among Indigenous Australians. Australian and New Zealand Journal of Public Health, 2010, 34, S47-S51.	1.8	49
238	Stimulant and other substance use disorders in schizophrenia: Prevalence, correlates and impacts in a population sample. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1036-1047.	2.3	49
239	Refining the excretion factors of methadone and codeine for wastewater analysis — Combining data from pharmacokinetic and wastewater studies. Environment International, 2016, 94, 307-314.	10.0	49
240	How do we define the policy impact of public health research? A systematic review. Health Research Policy and Systems, 2017, 15, 84.	2.8	49
241	Management and treatment efficacy of drug and alcohol problems: what do doctors believe?. Addiction, 1995, 90, 1357-1366.	3.3	49
242	The THC content of cannabis in Australia: evidence and implications. Australian and New Zealand Journal of Public Health, 2000, 24, 503-508.	1.8	48
243	Cannabis Use in Canada: The Need for a â€ [~] Public Health' Approach. Canadian Journal of Public Health, 2009, 100, 101-103.	2.3	48
244	Galvanizers, Guides, Champions, and Shields: The Many Ways That Policymakers Use Public Health Researchers. Milbank Quarterly, 2011, 89, 564-598.	4.4	48
245	The structure and correlates of alcohol dependence: WHO collaborative project on the early detection of persons with harmful alcohol consumption-III. Addiction, 1993, 88, 1627-1636.	3.3	47
246	The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 2006, 1, 11.	2.2	47
247	Testing for cannabis in the workâ€place: a review of the evidence. Addiction, 2010, 105, 408-416.	3.3	47
248	What are the major drivers of prevalent disability burden in young Australians?. Medical Journal of Australia, 2011, 194, 232-235.	1.7	47
249	Prevalence and predictors of psychopathology among opioid users. Addiction, 1992, 87, 771-776.	3.3	46
250	HIV risk-taking behaviour among amphetamine users in Sydney, Australia. Addiction, 1994, 89, 79-85.	3.3	46
251	Back-projection estimates of the number of dependent heroin users in Australia. Addiction, 2001, 96, 433-443.	3.3	46
252	Alcohol and cannabis: Comparing their adverse health effects and regulatory regimes. International Journal of Drug Policy, 2017, 42, 57-62.	3.3	46

#	Article	IF	CITATIONS
253	Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology, 2022, 239, 1509-1519.	3.1	46
254	Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug and Alcohol Review, 1994, 13, 277-284.	2.1	45
255	The effect of a reduction in heroin supply on fatal and nonâ€fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia, 2005, 182, 20-23.	1.7	45
256	The effects of partial decriminalisation on cannabis use in South Australia, 1985 to 1993. Australian Journal of Public Health, 1995, 19, 281-287.	0.2	45
257	ls cannabis use psychotogenic?. Lancet, The, 2006, 367, 193-195.	13.7	44
258	Being More Realistic about the Public Health Impact of Genomic Medicine. PLoS Medicine, 2010, 7, e1000347.	8.4	44
259	Australian University Students' Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers. Frontiers in Psychology, 2016, 7, 277.	2.1	44
260	The challenge of reducing smoking in people with serious mental illness. Lancet Respiratory Medicine,the, 2016, 4, 835-844.	10.7	44
261	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. Addiction, 2022, 117, 1510-1517.	3.3	44
262	Current and future perspectives for wastewater-based epidemiology as a monitoring tool for pharmaceutical use. Science of the Total Environment, 2021, 789, 148047.	8.0	44
263	The effects of the Cannabis Expiation Notice system on the prevalence of cannabis use in South Australia: evidence from the National Drug Strategy Household Surveys 1985-95. Drug and Alcohol Review, 2000, 19, 265-269.	2.1	43
264	Reducing the harms caused by cannabis use: the policy debate in Australiaâ~†. Drug and Alcohol Dependence, 2001, 62, 163-174.	3.2	43
265	How have the Selective Serotonin Reuptake Inhibitor Antidepressants Affected Suicide Mortality?. Australian and New Zealand Journal of Psychiatry, 2006, 40, 941-950.	2.3	43
266	A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women. Psychological Medicine, 2012, 42, 1273-1282.	4.5	43
267	How is acceptance of the brain disease model of addiction related to Australians' attitudes towards addicted individuals and treatments for addiction?. BMC Psychiatry, 2014, 14, 373.	2.6	43
268	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. Pain, 2016, 157, 1489-1498.	4.2	43
269	Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. Addiction, 2018, 113, 1811-1825.	3.3	43
270	Australia's mental health: an overview of the general population survey*. Australian and New Zealand Journal of Psychiatry, 2000, 34, 197-205.	2.3	43

#	Article	IF	CITATIONS
271	â€~Repetition strain injury': An Australian epidemic of upper limb pain. Social Science and Medicine, 1988, 27, 645-649.	3.8	42
272	Anxiety, Depression and HIV Related Symptomatology across the Spectrum of HIV Disease. Australian and New Zealand Journal of Psychiatry, 1992, 26, 560-566.	2.3	42
273	Hiv Risk Behaviour of Idus Before, During and After Imprisonment in New South Wales. Addiction Research, 1996, 4, 151-160.	0.6	42
274	The prospects for immunotherapy in smoking cessation. Lancet, The, 2002, 360, 1089-1091.	13.7	42
275	The "alcopops―tax: heading in the right direction. Medical Journal of Australia, 2009, 190, 294-295.	1.7	42
276	The epidemiology of cannabis use and cannabisâ€related harm in Australia 1993–2007. Addiction, 2010, 105, 1071-1079.	3.3	42
277	Prescription Drug Utilization Following Patient Co-Payment Changes in Australia. , 1996, 5, 385-392.		41
278	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 566-574.	1.9	41
279	Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 2007, 186, 152-153.	1.7	41
280	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. PLoS Medicine, 2009, 6, e1000133.	8.4	41
281	A systematic review and metaâ€analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review, 2014, 33, 115-128.	2.1	41
282	Vaping on TikTok: a systematic thematic analysis. Tobacco Control, 2023, 32, 251-254.	3.2	41
283	Methadone maintenance and the human immunodeficiency virus: current issues in treatment and research. Addiction, 1992, 87, 447-453.	3.3	40
284	Per capita alcohol consumption in Australia: will the real trend please step forward?. Medical Journal of Australia, 2010, 193, 594-597.	1.7	40
285	Proposals to trial deep brain stimulation to treat addiction are premature. Addiction, 2011, 106, 235-237.	3.3	40
286	Psychological Distress is Associated with Tobacco Smoking and Quitting Behaviour in the Australian Population: Evidence from National Cross-Sectional Surveys. Australian and New Zealand Journal of Psychiatry, 2011, 45, 170-178.	2.3	40
287	Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction, 2015, 110, 1061-1067.	3.3	40
288	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 2016, 162, 79-87.	3.2	40

#	Article	IF	CITATIONS
289	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World Journal of Biological Psychiatry, 2022, 23, 719-742.	2.6	40
290	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 2014, 15, 17.	2.4	39
291	High potency cannabis. BMJ, The, 2015, 350, h1205-h1205.	6.0	39
292	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. Clinical Journal of Pain, 2016, 32, 292-301.	1.9	39
293	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiology and Drug Safety, 2017, 26, 587-591.	1.9	39
294	Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology, 2021, 193, 108610.	4.1	39
295	Cohort trends in age of initiation to heroin use. Drug and Alcohol Review, 1998, 17, 289-297.	2.1	38
296	Stereotactic neurosurgical treatment of addiction: minimizing the chances of another â€~great and desperate cure'. Addiction, 2006, 101, 1-3.	3.3	38
297	The Mental Health Risks of Adolescent Cannabis Use. PLoS Medicine, 2006, 3, e39.	8.4	38
298	Rural and Urban Differences in Adolescent Alcohol Use, Alcohol Supply, and Parental Drinking. Journal of Rural Health, 2016, 32, 280-286.	2.9	38
299	Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction, 1997, 92, 697-705.	3.3	37
300	Cannabis use and cancer. Addiction, 2002, 97, 243-247.	3.3	37
301	Neuroscience research on the addictions: A prospectus for future ethical and policy analysis. Addictive Behaviors, 2004, 29, 1481-1495.	3.0	37
302	It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction, 2018, 113, 987-988.	3.3	37
303	The Effects of Cannabis Use on the Development of Adolescents and Young Adults. Annual Review of Developmental Psychology, 2020, 2, 461-483.	2.9	37
304	Prevalence of Adolescent Cannabis Vaping. JAMA Pediatrics, 2022, 176, 42.	6.2	37
305	Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia. Addiction, 1993, 88, 509-516.	3.3	36
306	Predictors of increased mortality in elderly depressed patients. International Journal of Geriatric Psychiatry, 1994, 9, 219-227.	2.7	36

#	Article	IF	CITATIONS
307	The Role of Legal Coercion in the Treatment of Offenders with Alcohol and Heroin Problems. Australian and New Zealand Journal of Criminology, 1997, 30, 103-120.	2.5	36
308	The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review, 2008, 27, 145-151.	2.1	36
309	[Commentary] ADOLESCENT CANNABIS USE AND ADULT LIFE CHANCES. Addiction, 2008, 103, 977-978.	3.3	36
310	A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice. Australian Journal of Public Health, 1995, 19, 142-148.	0.2	36
311	Property Crime and Income Generation by Heroin Users. Australian and New Zealand Journal of Criminology, 2002, 35, 187-202.	2.5	35
312	Ethical Concerns in the Community About Technologies to Extend Human Life Span. American Journal of Bioethics, 2009, 9, 68-76.	0.9	35
313	The Association between Four Citation Metrics and Peer Rankings of Research Influence of Australian Researchers in Six Fields of Public Health. PLoS ONE, 2011, 6, e18521.	2.5	35
314	The genetics of nicotine addiction liability: ethical and social policy implications. Addiction, 2008, 103, 350-359.	3.3	34
315	Academic doping or Viagra for the brain?. EMBO Reports, 2011, 12, 197-201.	4.5	34
316	Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction. Addiction, 2012, 107, 1891-1893.	3.3	34
317	Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiology and Drug Safety, 2015, 24, 628-636.	1.9	34
318	Parental supply of alcohol to Australian minors: an analysis of six nationally representative surveys spanning 15Âyears. BMC Public Health, 2016, 16, 325.	2.9	34
319	Monitoring temporal changes in use of two cathinones in a large urban catchment in Queensland, Australia. Science of the Total Environment, 2016, 545-546, 250-255.	8.0	34
320	E-cigarettes and the law in Australia. Australian Family Physician, 2015, 44, 415-8.	0.5	34
321	On "the lateralization of pain― Pain, 1981, 10, 337-351.	4.2	33
322	An overview of diversion strategies for Australian drugâ€related offenders. Drug and Alcohol Review, 2001, 20, 281-294.	2.1	33
323	Medical Marijuana Initiatives. CNS Drugs, 2003, 17, 689-697.	5.9	33
324	Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 2004, 329, 428-429.	2.3	33

#	Article	IF	CITATIONS
325	WHAT'S IN A NAME?. Addiction, 2007, 102, 692-692.	3.3	33
326	Sociodemographic correlates of antidepressant utilisation in Australia. Medical Journal of Australia, 2009, 190, 479-483.	1.7	33
327	The challenges in developing a rational cannabis policy. Current Opinion in Psychiatry, 2009, 22, 258-262.	6.3	33
328	Alcohol policy reform in Australia: what can we learn from the evidence?. Medical Journal of Australia, 2010, 192, 468-470.	1.7	33
329	Ethical Issues Raised by Proposals to Treat Addiction Using Deep Brain Stimulation. Neuroethics, 2011, 4, 129-142.	2.8	33
330	Psychosis in Indigenous populations of Cape York and the Torres Strait. Medical Journal of Australia, 2012, 196, 133-135.	1.7	33
331	Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife. American Journal of Psychiatry, 2022, 179, 362-374.	7.2	33
332	Trends in the use of cannabis products in Canada and the USA, 2018 – 2020: Findings from the International Cannabis Policy Study. International Journal of Drug Policy, 2022, 105, 103716.	3.3	33
333	Under what conditions is it ethical to offer incentives to encourage drugâ€using women to use longâ€acting forms of contraception?. Addiction, 2012, 107, 1036-1041.	3.3	32
334	Realâ€ŧime monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia, 2013, 198, 80-81.	1.7	32
335	Can Localised Brain Impairment Be Simulated on Neuropsychological Test Profiles?. Australian and New Zealand Journal of Psychiatry, 1987, 21, 87-93.	2.3	31
336	Benzodiazepine prescribing in general practice: dispelling some myths. Family Practice, 1995, 12, 37-43.	1.9	31
337	Analysis of socio-political and health practices influencing sex ratio at birth in Viet Nam. Reproductive Health Matters, 2008, 16, 176-184.	1.2	31
338	Who is responsible for the public's health? The role of the alcohol industry in the WHO global strategy to reduce the harmful use of alcohol. Addiction, 2013, 108, 2045-2047.	3.3	31
339	Reaching "An Audience That You Would Never Dream of Speaking Toâ€: Influential Public Health Researchers' Views on the Role of News Media in Influencing Policy and Public Understanding. Journal of Health Communication, 2014, 19, 260-273.	2.4	31
340	Researchers' perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey. Scientific Reports, 2015, 5, 10618.	3.3	31
341	The future of the international drug control system and national drug prohibitions. Addiction, 2018, 113, 1210-1223.	3.3	31
342	An overview of select cannabis use and supply indicators pre- and post-legalization in Canada. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 77.	2.2	31

#	Article	IF	CITATIONS
343	Alpha 1 antitrypsin phenotypes and alcoholic pancreatitis Gut, 1991, 32, 945-948.	12.1	30
344	Benzodiazepine use among heroin users in Sydney: patterns of use, availability and procurement. Drug and Alcohol Review, 1996, 15, 237-243.	2.1	30
345	Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 2006, 25, 307-313.	2.1	30
346	Cigarette tax and public health: what are the implications of financially stressed smokers for the effects of price increases on smoking prevalence?. Addiction, 2011, 106, 622-630.	3.3	30
347	Lessons for Enhancement From the History of Cocaine and Amphetamine Use. AJOB Neuroscience, 2012, 3, 24-29.	1.1	30
348	Is the socioeconomic gap in childhood exposure to secondhand smoke widening or narrowing?. Tobacco Control, 2013, 22, 344-348.	3.2	30
349	Views of Addiction Neuroscientists and Clinicians on the Clinical Impact of a â€~Brain Disease Model of Addiction'. Neuroethics, 2014, 7, 19-27.	2.8	30
350	The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 2005, 79, 129-135.	3.2	29
351	Informed consent to opioid agonist maintenance treatment: Recommended ethical guidelines. International Journal of Drug Policy, 2008, 19, 79-89.	3.3	29
352	A longitudinal evaluation of a project-based learning initiative in an engineering undergraduate programme. European Journal of Engineering Education, 2012, 37, 155-165.	2.3	29
353	Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry, 2014, 14, 74.	2.6	29
354	What Have Been the Public Health Impacts of Cannabis Legalisation in the USA? A Review of Evidence on Adverse and Beneficial Effects. Current Addiction Reports, 2019, 6, 418-428.	3.4	29
355	A Simplified Logic of Causal Inference. Australian and New Zealand Journal of Psychiatry, 1987, 21, 507-513.	2.3	28
356	Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology, 1994, 106, 742-748.	1.3	28
357	Thinking about the unthinkable: a <i>de facto</i> prohibition on smoked tobacco products. Addiction, 2008, 103, 873-874.	3.3	28
358	The adverse effects of cannabinoids: implications for use of medical marijuana. Cmaj, 2008, 178, 1685-1686.	2.0	28
359	Profiling Hello Sunday Morning: Who are the participants?. International Journal of Drug Policy, 2015, 26, 214-216.	3.3	28
360	The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications. Addiction, 2018, 113, 595-601.	3.3	28

#	Article	IF	CITATIONS
361	Clinical management of cannabis withdrawal. Addiction, 2022, 117, 2075-2095.	3.3	28
362	Statistical Power in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1986, 20, 189-200.	2.3	27
363	Methadone maintenance treatment in prisons: The New South Wales Experience. Drug and Alcohol Review, 1993, 12, 193-203.	2.1	27
364	Preventing drug misuse by young people: we need to do more than â€j̃ust say no'. Addiction, 2002, 97, 478-481.	3.3	27
365	Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction, 2009, 104, 118-126.	3.3	27
366	Is There Evidence of â€~Hardening' Among Australian Smokers Between 1997 and 2007? Analyses of the Australian National Surveys of Mental Health and Well-Being. Australian and New Zealand Journal of Psychiatry, 2010, 44, 1132-1136.	2.3	27
367	Stimulant use disorders: Characteristics and comorbidity in an Australian population sample. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1173-1181.	2.3	27
368	Challenges and opportunities in using wastewater analysis to measure drug use in a small prison facility. Drug and Alcohol Review, 2016, 35, 138-147.	2.1	27
369	Social class and survival on the S.S. Titanic. Social Science and Medicine, 1986, 22, 687-690.	3.8	26
370	Hyperactivity and the Fragile X Syndrome. Journal of Abnormal Child Psychology, 1991, 19, 253-262.	3.5	26
371	A bleach program for inmates in NSW: an HIV prevention strategy. Australian and New Zealand Journal of Public Health, 1998, 22, 838-840.	1.8	26
372	Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Australian and New Zealand Journal of Public Health, 2000, 24, 603-606.	1.8	26
373	Will Nicotine Genetics and a Nicotine Vaccine Prevent Cigarette Smoking and Smoking-Related Diseases?. PLoS Medicine, 2005, 2, e266.	8.4	26
374	Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?. Addiction, 2012, 107, 241-247.	3.3	26
375	Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis. British Journal of Psychiatry, 2014, 204, 448-453.	2.8	26
376	Evidence of HIV transmission in an Australian prison. Medical Journal of Australia, 1994, 160, 734-734.	1.7	25
377	The respiratory risks of cannabis smoking. Addiction, 1998, 93, 1461-1463.	3.3	25
378	Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics, 2004, 30, 337-340.	1.8	25

#	Article	IF	CITATIONS
379	Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. Journal of Molecular Medicine, 2004, 82, 21-30.	3.9	25
380	Who wants to live forever?. EMBO Reports, 2005, 6, 98-102.	4.5	25
381	British drinking: a suitable case for treatment?. BMJ: British Medical Journal, 2005, 331, 527-528.	2.3	25
382	Navigating the enhancement landscape. EMBO Reports, 2013, 14, 123-128.	4.5	25
383	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, 1277-1277.	2.7	25
384	What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. International Review of Psychiatry, 2018, 30, 91-106.	2.8	25
385	A Systematic Review of Trends in US Attitudes toward Cannabis Legalization. Substance Use and Misuse, 2022, 57, 1052-1061.	1.4	25
386	Why Do They Do It?. Public Health Genomics, 2007, 10, 61-71.	1.0	24
387	Community perceptions on the significant extension of life: An exploratory study among urban adults in Brisbane, Australia. Social Science and Medicine, 2009, 68, 496-503.	3.8	24
388	Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Current Opinion in Psychiatry, 2011, 24, 191-196.	6.3	24
389	A Comparison of Attitudes Toward Cognitive Enhancement and Legalized Doping in Sport in a Community Sample of Australian Adults. American Journal of Bioethics Primary Research, 2012, 3, 81-86.	1.5	24
390	Generational Increase in Young Women's Drinking. JAMA Psychiatry, 2014, 71, 952.	11.0	24
391	Alcohol burden in low-income and middle-income countries. Lancet, The, 2015, 386, 1922-1924.	13.7	24
392	Parental supply of alcohol and adolescent drinking: a multilevel analysis of nationally representative data. BMC Public Health, 2017, 17, 560.	2.9	24
393	Understanding the true economic impact of self-harming behaviour. Lancet Psychiatry,the, 2017, 4, 900-901.	7.4	24
394	Psychiatric Impairment, Physical Health and Work Values among Unemployed and Apprenticed Young Men. Australian and New Zealand Journal of Psychiatry, 1983, 17, 335-340.	2.3	23
395	Addiction, neuroscience and ethics. Addiction, 2003, 98, 867-870.	3.3	23
396	â€~Occasional' and â€~social' smokers: potential target groups for smoking cessation campaigns?. Australian and New Zealand Journal of Public Health, 2006, 30, 550-554.	1.8	23

#	Article	IF	CITATIONS
397	The Issue of Consent in Research that Administers Drugs of Addiction to Addicted Persons. Accountability in Research, 2008, 15, 209-225.	2.4	23
398	Directâ€toâ€consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. Addiction, 2012, 107, 2069-2074.	3.3	23
399	Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophrenia Research, 2013, 147, 216-222.	2.0	23
400	Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Australian and New Zealand Journal of Public Health, 2013, 37, 132-138.	1.8	23
401	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. Drug and Alcohol Dependence, 2019, 205, 107533.	3.2	23
402	Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo Simulation. Addiction, 2020, 115, 1182-1186.	3.3	23
403	Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. Drug and Alcohol Review, 2001, 20, 193-199.	2.1	22
404	The prediction of disease risk in genomic medicine. EMBO Reports, 2004, 5, S22-6.	4.5	22
405	Management and treatment efficacy of drug and alcohol problems: what do doctors believe?. Addiction, 2006, 90, 1357-1366.	3.3	22
406	Ethical, Social, and Personal Implications of Extended Human Lifespan Identified by Members of the Public. Rejuvenation Research, 2009, 12, 351-357.	1.8	22
407	Weak evidence for large claims contribute to the phantom debate. BioSocieties, 2010, 5, 482-483.	1.3	22
408	Depression and psychological distress in tobacco smokers and people with cannabis dependence in the National Survey of Mental Health and Wellbeing. Medical Journal of Australia, 2011, 195, S12-5.	1.7	22
409	Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Australian and New Zealand Journal of Psychiatry, 2012, 46, 958-965.	2.3	22
410	The neurobiology of overeating. EMBO Reports, 2012, 13, 785-790.	4.5	22
411	Brain disease model of addiction: misplaced priorities?. Lancet Psychiatry,the, 2015, 2, 867.	7.4	22
412	Predictors of retention in a randomised trial of smoking cessation in low-socioeconomic status Australian smokers. Addictive Behaviors, 2017, 64, 13-20.	3.0	22
413	Youngâ€∎dult compared to adolescent onset of regular cannabis use: A 20â€year prospective cohort study of later consequences. Drug and Alcohol Review, 2021, 40, 627-636.	2.1	22
414	The costs and benefits of cannabis control policies. Dialogues in Clinical Neuroscience, 2020, 22, 281-287.	3.7	22

#	Article	IF	CITATIONS
415	Injecting and sexual risk-taking behaviour among regular amphetamine users. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1995, 7, 19-26.	1.2	21
416	THE 1998 JAMES RANKIN ORATION: Reducing the toll of opioid overdose deaths in Australia. Drug and Alcohol Review, 1999, 18, 213-220.	2.1	21
417	Cohort Trends in Youth Suicide in Australia 1964–1997. Australian and New Zealand Journal of Psychiatry, 2000, 34, 408-412.	2.3	21
418	Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime?. BMC Public Health, 2005, 5, 40.	2.9	21
419	Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 2006, 25, 297-305.	2.1	21
420	How Will Information About the Genetic Risk of Mental Disorders Impact on Stigma?. Australian and New Zealand Journal of Psychiatry, 2008, 42, 214-220.	2.3	21
421	Scare-Mongering and the Anticipatory Ethics of Experimental Technologies. American Journal of Bioethics, 2009, 9, 47-48.	0.9	21
422	Supping with the Devil? The role of law in promoting tobacco harm reduction using low nitrosamine smokeless tobacco products. Public Health, 2009, 123, 287-291.	2.9	21
423	Harm reduction policies for tobacco users. International Journal of Drug Policy, 2010, 21, 129-130.	3.3	21
424	The public perception of the risks and benefits of alcohol consumption. Australian Journal of Public Health, 1992, 16, 38-42.	0.2	21
425	Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia. Medical Journal of Australia, 2011, 195, 248-249.	1.7	21
426	Public attitudes in <scp>A</scp> ustralia towards the claim that addiction is a (brain) disease. Drug and Alcohol Review, 2014, 33, 272-279.	2.1	21
427	Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. BMC Public Health, 2018, 18, 1270.	2.9	21
428	On "Ratio scales of sensory and affective verbal pain descriptors― Pain, 1981, 11, 101-107.	4.2	20
429	Patterns of alcohol consumption in the Kimberley Aboriginal population. Medical Journal of Australia, 1992, 156, 764-768.	1.7	20
430	Methadone Maintenance Therapy for Opioid Dependence. CNS Drugs, 1996, 6, 440-449.	5.9	20
431	Characteristics of Long-Term Cannabis Users in Sydney, Australia. European Addiction Research, 1998, 4, 190-197.	2.4	20
432	The contribution of research to Australian policy responses to heroin dependence 1990-2001: a personal retrospection. Addiction, 2004, 99, 560-569.	3.3	20

#	Article	IF	CITATIONS
433	The integrity of the science base: a test case. Addiction, 2005, 100, 581-584.	3.3	20
434	Substance Use and Mental Health in Longitudinal Perspective. , 0, , 43-51.		20
435	Estimating the burden of disease attributable to illicit drug use and mental disorders: what is â€~Clobal Burden of Disease 2005' and why does it matter?. Addiction, 2009, 104, 1466-1471.	3.3	20
436	The public health significance of cannabis use in Australia. Australian Journal of Public Health, 1995, 19, 235-242.	0.2	20
437	Analysis of national data shows mixed evidence of hardening among Australian smokers. Australian and New Zealand Journal of Public Health, 2012, 36, 408-414.	1.8	20
438	What does â€~acceptance' mean? Public reflections on the idea that addiction is a brain disease. BioSocieties, 2013, 8, 491-506.	1.3	20
439	Association between purity of drug seizures and illicit drug loads measured in wastewater in a South East Queensland catchment over a six year period. Science of the Total Environment, 2018, 635, 779-783.	8.0	20
440	Miscommunication about the causes of the US outbreak of lung diseases in vapers by public health authorities and the media. Drug and Alcohol Review, 2020, 39, 3-6.	2.1	20
441	Simultaneous Multiple Comparison Procedures for Categorical Data. Australian and New Zealand Journal of Psychiatry, 1986, 20, 350-359.	2.3	19
442	The recent Australian debate about the prohibition on cannabis use. Addiction, 1997, 92, 1109-1116.	3.3	19
443	Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health, 2001, 25, 447-450.	1.8	19
444	An invitation to an alcohol industry lobby to help decide public funding of alcohol research and professional training: a decision that should be reversed. Addiction, 2004, 99, 1235-1236.	3.3	19
445	Drug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis. Neuroethics, 2011, 4, 91-102.	2.8	19
446	Cannabis and the increased incidence and persistence of psychosis. BMJ: British Medical Journal, 2011, 342, d719-d719.	2.3	19
447	Monitoring substance use in prisons: Assessing the potential value of wastewater analysis. Science and Justice - Journal of the Forensic Science Society, 2014, 54, 338-345.	2.1	19
448	The Use of Cannabinoids in Treating Dementia. Current Neurology and Neuroscience Reports, 2017, 17, 56.	4.2	19
449	Cannabinoids for the treatment of spasticity. Developmental Medicine and Child Neurology, 2019, 61, 631-638.	2.1	19
450	Cannabis use and mental health: risks and benefits. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 1-3.	3.2	19

#	Article	IF	CITATIONS
451	Correlates of electronic cigarette use in the general population and among smokers in Australia – Findings from a nationally representative survey. Addictive Behaviors, 2019, 95, 6-10.	3.0	19
452	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological Medicine, 2023, 53, 3858-3868.	4.5	19
453	The incidence of schizophrenia in New South Wales, Australia Acta Psychiatrica Scandinavica, 1984, 70, 220-227.	4.5	18
454	Simultaneous Multiple Comparison Procedures in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1986, 20, 46-54.	2.3	18
455	Comparisons of psychological and social factors in patients with chronic oroâ€facial pain and dental phobic disorders*. Australian Dental Journal, 1987, 32, 331-335.	1.5	18
456	An evaluation of Cloninger's typology of alcohol abuse. Addiction, 1998, 93, 1241-1249.	3.3	18
457	Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders. Drug and Alcohol Review, 2001, 20, 369-383.	2.1	18
458	A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control, 2007, 16, 53-58.	3.2	18
459	Depot naltrexone use for opioid dependence in Australia: largeâ€scale use of an unregistered medication in the absence of data on safety and efficacy. Drug and Alcohol Review, 2008, 27, 1-3.	2.1	18
460	Public attitudes towards alcohol control policies. Australian Journal of Public Health, 1991, 15, 301-306.	0.2	18
461	Letter to the Editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase, 2012, 18, 181-184.	0.6	18
462	Excess mortality among opioidâ€using patients treated with oral naltrexone in <scp>A</scp> ustralia. Drug and Alcohol Review, 2015, 34, 90-96.	2.1	18
463	Trends in methamphetamine residues in wastewater in metropolitan and regional cities in southâ€east Queensland, 2009–2015. Medical Journal of Australia, 2016, 204, 151-152.	1.7	18
464	Trend in alcohol use in Australia over 13Âyears: has there been a trend reversal?. BMC Public Health, 2016, 16, 1070.	2.9	18
465	Disease or Developmental Disorder: Competing Perspectives on the Neuroscience of Addiction. Neuroethics, 2017, 10, 103-110.	2.8	18
466	Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. EClinicalMedicine, 2020, 20, 100294.	7.1	18
467	Content analysis of cannabis vaping videos on YouTube. Addiction, 2021, 116, 2443-2453.	3.3	18
468	Why was early therapeutic research on psychedelic drugs abandoned?. Psychological Medicine, 2022, 52, 26-31.	4.5	18

#	Article	IF	CITATIONS
469	Pain and laterality in a British pain clinic sample. Pain, 1982, 14, 63-66.	4.2	17
470	Does Depressive Illness in the Elderly Have a Poor Prognosis?. Australian and New Zealand Journal of Psychiatry, 1986, 20, 422-427.	2.3	17
471	Depression Sub-Typing: Unitary, Binary or Arbitrary?. Australian and New Zealand Journal of Psychiatry, 1991, 25, 63-76.	2.3	17
472	Behavior phenotype of the fragile X syndrome. American Journal of Medical Genetics Part A, 1992, 43, 56-60.	2.4	17
473	Assessing the wisdom of funding DrinkWise. Medical Journal of Australia, 2006, 185, 635-636.	1.7	17
474	The search for Methuselah. EMBO Reports, 2007, 8, 888-891.	4.5	17
475	The contribution of research to the development of a national cannabis policy in Australia. Addiction, 2008, 103, 712-720.	3.3	17
476	The use of depot naltrexone under legal coercion: the case for caution. Addiction, 2008, 103, 1922-1924.	3.3	17
477	Public attitudes towards human life extension by intervening in ageing. Journal of Aging Studies, 2011, 25, 73-83.	1.4	17
478	Does the social context of early alcohol use affect risky drinking in adolescents? Prospective cohort study. BMC Public Health, 2015, 15, 1137.	2.9	17
479	Tobacco harm reduction in people with serious mental illnesses. Lancet Psychiatry,the, 2015, 2, 485-487.	7.4	17
480	How Much Can the USA Reduce Health Care Costs by Reducing Smoking?. PLoS Medicine, 2016, 13, e1002021.	8.4	17
481	A qualitative study of overweight and obese Australians' views of food addiction. Appetite, 2017, 115, 62-70.	3.7	17
482	Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety, 2020, 29, 1325-1330.	1.9	17
483	The characteristics of cocaine users among young adults in Sydney. Medical Journal of Australia, 1991, 155, 11-14.	1.7	16
484	The Health and Psychological Effects of Cannabis Use. Current Issues in Criminal Justice, 1994, 6, 208-220.	1.4	16
485	Changes in the public perceptions of the health benefits of alcohol use, 1989 to 1994. Australian and New Zealand Journal of Public Health, 1996, 20, 93-95.	1.8	16
486	A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence, 1998, 50, 197-202.	3.2	16

#	Article	IF	CITATIONS
487	HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. Drug and Alcohol Review, 1999, 18, 139-143.	2.1	16
488	Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. Addiction, 2007, 102, 1685-1688.	3.3	16
489	[Commentary] THE POTENTIAL ROLE OF SNUS IN TOBACCO HARM REDUCTION. Addiction, 2009, 104, 1586-1587.	3.3	16
490	Utilization of antiâ€Parkinson drugs in Australia: 1995–2009. Pharmacoepidemiology and Drug Safety, 2011, 20, 450-456.	1.9	16
491	Management of impulse control disorders in Parkinson's disease. International Psychogeriatrics, 2016, 28, 1597-1614.	1.0	16
492	Scepticism and hope in a complex predicament: People with addictions deliberate about neuroscience. International Journal of Drug Policy, 2016, 32, 34-43.	3.3	16
493	Alcohol consumption and consequences in adolescents in 68 low and middle-income countries – a multi-country comparison of risks by sex. Drug and Alcohol Dependence, 2019, 205, 107520.	3.2	16
494	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine, 2020, 28, 100592.	7.1	16
495	Challenge of reducing drug-related deaths. Lancet, The, 2000, 356, 7-8.	13.7	15
496	ls there a specific â€~cannabis psychosis'?. , 2004, , 89-100.		15
497	Reprint of "Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base― Addictive Behaviors, 2009, 34, 795-799.	3.0	15
498	The Australian alcopops tax revisited. Lancet, The, 2011, 377, 1136-1137.	13.7	15
499	Alcohol, Tobacco, and Prescription Drugs: The Relationship With Illicit Drugs in the Treatment of Substance Users. Substance Use and Misuse, 2012, 47, 963-971.	1.4	15
500	Should doctors prescribe cannabinoids?. BMJ, The, 2014, 348, g2737-g2737.	6.0	15
501	Compulsory treatment of addiction in the patient's best interests: More rigorous evaluations are essential. Drug and Alcohol Review, 2014, 33, 268-271.	2.1	15
502	Estimated verbal IQ and the odds of problem gambling: a population-based study. Psychological Medicine, 2014, 44, 1739-1749.	4.5	15
503	Public Understandings of Addiction: Where do Neurobiological Explanations Fit?. Neuroethics, 2014, 7, 51-62.	2.8	15
504	Heroin-assisted treatment: has a controversial treatment come of age?. British Journal of Psychiatry, 2015, 207, 3-4.	2.8	15

#	Article	IF	CITATIONS
505	The is and ought of the Ethics of Neuroenhancement: Mind the Gap. Frontiers in Psychology, 2016, 6, 1998.	2.1	15
506	Thresholds for safer alcohol use might need lowering. Lancet, The, 2018, 391, 1460-1461.	13.7	15
507	Reducing the opioid overdose death toll in North America. PLoS Medicine, 2018, 15, e1002626.	8.4	15
508	Strategies to reduce drug-related harm: responding to the evidence base. Lancet, The, 2019, 394, 1490-1493.	13.7	15
509	How can we reduce heroin "overdose―deaths?. Medical Journal of Australia, 1996, 164, 197-198.	1.7	14
510	Allowing the medical use of cannabis. Medical Journal of Australia, 2001, 175, 39-40.	1.7	14
511	Challenges and Approaches to Estimating Mortality Attributable to the Use of Selected Illicit Drugs. European Addiction Research, 2001, 7, 104-116.	2.4	14
512	Public policy and the prevention of substance-use disorders. Current Opinion in Psychiatry, 2002, 15, 235-239.	6.3	14
513	Being realistic about benefits of supervised injecting facilities. Lancet, The, 2005, 366, 271-272.	13.7	14
514	When is a Behavioural Phenotype Not a Phenotype?. Developmental Medicine and Child Neurology, 1994, 36, 467-470.	2.1	14
515	Mental Disorders and Socioeconomic Status: Impact on Population Risk of Attempted Suicide in Australia. Suicide and Life-Threatening Behavior, 2009, 39, 471-481.	1.9	14
516	Why we need tobacco sales data for good tobacco control. Medical Journal of Australia, 2010, 192, 3-4.	1.7	14
517	Commentary on <scp>O</scp> rt <i>et al</i> . (2014): What next to deliver on the promise of large scale sewageâ€based drug epidemiology?. Addiction, 2014, 109, 1353-1354.	3.3	14
518	Control and Responsibility in Addicted Individuals: What do Addiction Neuroscientists and Clinicians Think?. Neuroethics, 2014, 7, 205-214.	2.8	14
519	Neuroscience in gambling policy and treatment: an interdisciplinary perspective. Lancet Psychiatry,the, 2017, 4, 501-506.	7.4	14
520	Framing Tobacco Dependence as a "Brain Diseaseâ€: Implications for Policy and Practice. Nicotine and Tobacco Research, 2017, 19, 774-780.	2.6	14
521	Ensuring access to safe, effective, and affordable cannabisâ€based medicines. British Journal of Clinical Pharmacology, 2020, 86, 630-634.	2.4	14
522	A wastewaterâ€based assessment of the impact of a minimum unit price (MUP) on population alcohol consumption in the Northern Territory, Australia. Addiction, 2022, 117, 243-249.	3.3	14

#	Article	IF	CITATIONS
523	Is deep brain stimulation a prospective "cure" for addiction?. F1000 Medicine Reports, 2011, 3, 4.	2.9	14
524	Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies. Pain Medicine, 2022, 23, 1442-1456.	1.9	14
525	Causal inference with observational data in addiction research. Addiction, 2022, 117, 2736-2744.	3.3	14
526	Rapid opiate detoxification treatment. Drug and Alcohol Review, 1997, 16, 325-327.	2.1	13
527	Factor Structure of Psychopathy Among Methadone Maintenance Patients. Journal of Personality Disorders, 1998, 12, 162-171.	1.4	13
528	Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage―in NSW, Australia. Drug and Alcohol Dependence, 2005, 79, 397-404.	3.2	13
529	Strong and weak lifespan extension: what is most feasible and likely?. Australasian Journal on Ageing, 2006, 25, 58-62.	0.9	13
530	Oral substitution treatments for opioid dependence. Lancet, The, 2008, 371, 2150-2151.	13.7	13
531	Should Australia lift its ban on low nitrosamine smokeless tobacco products?. Medical Journal of Australia, 2008, 188, 44-46.	1.7	13
532	Alcohol sales data are essential for good public policies towards alcohol. Medical Journal of Australia, 2008, 189, 188-189.	1.7	13
533	A randomized clinical trial of a financial education intervention with nicotine replacement therapy (<scp>NRT</scp>) for low socioâ€economic status <scp>A</scp> ustralian smokers: a study protocol. Addiction, 2014, 109, 1602-1611.	3.3	13
534	An analysis of policy levers used to implement mental health reform in Australia 1992-2012. BMC Health Services Research, 2015, 15, 479.	2.2	13
535	Lee Robins' studies of heroin use among US Vietnam veterans. Addiction, 2017, 112, 176-180.	3.3	13
536	Accurate identification of opioid overdose deaths using coronial data. Forensic Science International, 2018, 287, 40-46.	2.2	13
537	Socioâ€economic differentials in cannabis use trends in Australia. Addiction, 2018, 113, 454-461.	3.3	13
538	Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys. Addiction, 2019, 114, 61-70.	3.3	13
539	A comparison of trends in wastewaterâ€based data and traditional epidemiological indicators of stimulant consumption in three locations. Addiction, 2020, 115, 462-472.	3.3	13
540	Can wastewater analysis be used as a tool to assess the burden of pain treatment within a population?. Environmental Research, 2020, 188, 109769.	7.5	13

#	Article	IF	CITATIONS
541	A first pass, using preâ€history and contemporary history, at understanding why Australia and England have such different policies towards electronic nicotine delivery systems, 1970s– <i>c</i> . 2018. Addiction, 2021, 116, 2577-2585.	3.3	13
542	Do Cannabis Users Reduce Their THC Dosages When Using More Potent Cannabis Products? A Review. Frontiers in Psychiatry, 2021, 12, 630602.	2.6	13
543	Has increased youth e-cigarette use in the USA, between 2014 and 2020, changed conventional smoking behaviors, future intentions to smoke and perceived smoking harms?. Addictive Behaviors, 2021, 123, 107073.	3.0	13
544	Harm Minimization in a Prohibition Context—Australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	12
545	What does the community think about lifespan extension technologies? The need for an empirical base for ethical and policy debates. Australasian Journal on Ageing, 2006, 25, 180-184.	0.9	12
546	DISSECTING THE CAUSAL ANATOMY OF THE LINK BETWEEN CANNABIS AND OTHER ILLICIT DRUGS. Addiction, 2006, 101, 472-473.	3.3	12
547	Delivering on the promise of human stem ell research. What are the real barriers?. EMBO Reports, 2006, 7, 1188-1192.	4.5	12
548	The Social Implications of Neurobiological Explanations of Resistible Compulsions. American Journal of Bioethics, 2007, 7, 15-17.	0.9	12
549	[Commentary] REDUCING CANNABISâ€IMPAIRED DRIVING: IS THERE SUFFICIENT EVIDENCE FOR DRUG TESTING OF DRIVERS?. Addiction, 2007, 102, 1918-1919.	3.3	12
550	Estimates of the number of injecting drug users in a defined area. Australian Journal of Public Health, 1992, 16, 232-237.	0.2	12
551	Forecasting future tobacco control policy: where to next?. Australian and New Zealand Journal of Public Health, 2010, 34, 447-450.	1.8	12
552	How should we regulate smokeless tobacco products and eâ€cigarettes?. Medical Journal of Australia, 2012, 197, 611-612.	1.7	12
553	Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. Drug and Alcohol Review, 2013, 32, n/a-n/a.	2.1	12
554	Media and evidence-informed policy development: the case of mental health in Australia. Contemporary Social Science, 2015, 10, 160-170.	1.9	12
555	A licence to vape: Is it time to trial of a nicotine licensing scheme to allow Australian adults controlled access to electronic cigarettes devices and refill solutions containing nicotine?. International Journal of Drug Policy, 2015, 26, 548-553.	3.3	12
556	Long-term Marijuana Use and Cognitive Impairment in Middle Age. JAMA Internal Medicine, 2016, 176, 362.	5.1	12
557	Socioeconomic status and susceptibility to alcohol-related harm. Lancet Public Health, The, 2017, 2, e250-e251.	10.0	12
558	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. Pain Medicine, 2019, 20, 2450-2458.	1.9	12

#	Article	IF	CITATIONS
559	A Survey of Practising Psychiatrists' Views on the Treatment of Agoraphobia. Australian and New Zealand Journal of Psychiatry, 1982, 16, 225-233.	2.3	11
560	Do Vietnam Veterans Suffer from Toxic Neurasthenia?. Australian and New Zealand Journal of Psychiatry, 1985, 19, 19-29.	2.3	11
561	The logic of a controversy: The case of agent orange in Australia. Social Science and Medicine, 1989, 29, 537-544.	3.8	11
562	The drug market position of cocaine among young adults in Sydney. Addiction, 1990, 85, 891-897.	3.3	11
563	Issue of statistical power in comparative evaluations of minimal and intensive controlled drinking interventions. Addictive Behaviors, 1991, 16, 83-87.	3.0	11
564	Correlates of the perceived health risks of marijuana use among Australian adults. Drug and Alcohol Review, 1996, 15, 137-143.	2.1	11
565	Is naltrexone a cure for heroin dependence?. Medical Journal of Australia, 1999, 171, 9-10.	1.7	11
566	Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy, 2005, 16, 300-307.	3.3	11
567	Avoiding potential misuses of addiction brain science. Addiction, 2006, 101, 1529-1532.	3.3	11
568	Statins down under. British Journal of Clinical Pharmacology, 2007, 63, 125-127.	2.4	11
569	Standardizing terminology in addiction science: to achieve the impossible dream. Addiction, 2007, 102, 1015-1018.	3.3	11
570	Ending inequities in access to effective pain relief?. Lancet, The, 2010, 376, 856-857.	13.7	11
571	Psychiatric Drug Prescribing in Elderly Australians: Time for Action. Australian and New Zealand Journal of Psychiatry, 2011, 45, 705-708.	2.3	11
572	What place, if any, does information on putative cardioprotective effects of moderate alcohol use have in safer drinking guidelines?. Drug and Alcohol Review, 2012, 31, 194-197.	2.1	11
573	Does parental monitoring and disapproval explain variations in alcohol use among adolescents from different countries of birth?. Drug and Alcohol Review, 2016, 35, 741-749.	2.1	11
574	Regional versus urban differences in teenage alcohol use: Does parental disapproval account for these differences?. Australian Journal of Rural Health, 2016, 24, 3-8.	1.5	11
575	An analysis of policy success and failure in formal evaluations of Australia's national mental health strategy (1992–2012). BMC Health Services Research, 2017, 17, 374.	2.2	11
576	The Global Epidemiology and Disease Burden of Cannabis Use and Dependence. , 2017, , 89-100.		11

#	Article	IF	CITATIONS
577	Familial alcohol supply, adolescent drinking and early alcohol onset in 45 low and middle income countries. Addictive Behaviors, 2018, 84, 178-185.	3.0	11
578	Minimizing the adverse public health effects of cannabis legalization. Cmaj, 2018, 190, E1031-E1032.	2.0	11
579	A Neuroethics Framework for the Australian Brain Initiative. Neuron, 2019, 101, 365-369.	8.1	11
580	The effectiveness, safety and costâ€effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled nonâ€inferiority trial. Addiction, 2019, 114, 923-933.	3.3	11
581	The changing patterns and correlates of populationâ€level polysubstance use in Australian youth: a multiâ€group latent class analysis of nationally representative samples spanning 12 years. Addiction, 2020, 115, 145-155.	3.3	11
582	The effectiveness and safety of methadone maintenance. Addiction, 1996, 91, 1727-1728.	3.3	11
583	U.S. Policy Responses to Calls for the Medical Use of Cannabis. Yale Journal of Biology and Medicine, 2015, 88, 257-64.	0.2	11
584	The Agent Orange controversy after the Evatt Royal Commission. Medical Journal of Australia, 1986, 145, 219-225.	1.7	10
585	On Doing the "Impossible†Inferring that a Putative Causal Relationship does not Exist. Australian and New Zealand Journal of Psychiatry, 1990, 24, 217-226.	2.3	10
586	Are there two types of alcoholism?. Lancet, The, 1996, 348, 1258.	13.7	10
587	Debunking Alarmist Objections to the Pharmacological Prevention of PTSD. American Journal of Bioethics, 2007, 7, 23-25.	0.9	10
588	Clinical update: codeine maintenance in opioid dependence. Lancet, The, 2007, 370, 550-552.	13.7	10
589	Direct-to-Consumer Genome-Wide Scans: Astrologicogenomics or Simple Scams?. American Journal of Bioethics, 2009, 9, 54-56.	0.9	10
590	ASSESSING THE QUALITY OF DATA FOR ANALYSING THE SEX RATIO AT BIRTH IN VIET NAM. Asian Population Studies, 2010, 6, 263-287.	1.5	10
591	Conflicts of Interest in Recommendations to Use Computerized Neuropsychological Tests to Manage Concussion in Professional Football Codes. Neuroethics, 2014, 7, 63-74.	2.8	10
592	A Bio-Social and Ethical Framework for Understanding Fetal Alcohol Spectrum Disorders. Neuroethics, 2014, 7, 337-344.	2.8	10
593	How Did Youth Mental Health Make It Onto Australia's 2011 Federal Policy Agenda?. SAGE Open, 2016, 6, 215824401668085.	1.7	10
594	A qualitative study of smokers' views on brain-based explanations of tobacco dependence. International Journal of Drug Policy, 2016, 29, 41-48.	3.3	10

#	Article	IF	CITATIONS
595	Medicalisation, smoking and e-cigarettes: evidence and implications. Tobacco Control, 2017, 26, e134-e139.	3.2	10
596	A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. Lancet Public Health, The, 2019, 4, e77-e78.	10.0	10
597	The need for publicly funded research on therapeutic use of psychedelic drugs. World Psychiatry, 2021, 20, 197-198.	10.4	10
598	Cannabis use and the mental health of young people. Australian and New Zealand Journal of Psychiatry, 2006, 40, 105-113.	2.3	10
599	Illicit Drug Dependence. , 2016, , 109-125.		10
600	The Costs of Schizophrenia. Australian and New Zealand Journal of Psychiatry, 1985, 19, 3-5.	2.3	9
601	Early Sensory-Perceptual Changes in Huntington's Disease. Australian and New Zealand Journal of Psychiatry, 1985, 19, 384-389.	2.3	9
602	Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-92: I. Illicit drug problems. Drug and Alcohol Review, 1996, 15, 127-132.	2.1	9
603	Longitudinal research: methods for maximizing subject follow-up. Drug and Alcohol Review, 2000, 19, 159-163.	2.1	9
604	How common is comorbidity and why does it occur?. Australian Psychologist, 2005, 40, 81-87.	1.6	9
605	Ensuring that addiction science is deserving of public trust. Addiction, 2006, 101, 1223-1224.	3.3	9
606	The Implications of Genetic Susceptibility for the Prevention of Colorectal Cancer: A Qualitative Study of Older Adults' Understanding. Public Health Genomics, 2008, 11, 283-288.	1.0	9
607	The Australian Illicit Drug Reporting System: Monitoring Trends in Illicit Drug Availability, Use and Drug-Related Harm in Australia 1996–2006. Contemporary Drug Problems, 2009, 36, 643-661.	1.6	9
608	Drug trafficking: time to abolish the death penalty. Addiction, 2009, 104, 1267-1269.	3.3	9
609	Alcohol industry and government revenue derived from underage drinking by Australian adolescents 2005. Addictive Behaviors, 2009, 34, 75-81.	3.0	9
610	THE NEED FOR MORE EXPLANATORY HUMILITY IN ADDICTION NEUROBIOLOGY. Addiction, 2010, 105, 790-791.	3.3	9
611	Would vaccination against nicotine be a costâ€effective way to prevent smoking uptake in adolescents?. Addiction, 2012, 107, 801-809.	3.3	9
612	Public Attitudes Toward the Treatment of Nicotine Addiction. Nicotine and Tobacco Research, 2013, 15, 1617-1622.	2.6	9

#	Article	IF	CITATIONS
613	"lf you're healthy you don't need drugs― Public attitudes towards "brain doping―in the classrc and "legalised doping―in sport. Performance Enhancement and Health, 2014, 3, 20-25.	om 1.6	9
614	Rethinking cigarette smoking, cannabis use, and psychosis. Lancet Psychiatry,the, 2015, 2, 581-582.	7.4	9
615	Challenges in minimizing the adverse effects of cannabis use after legalization. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1013-1015.	3.1	9
616	Assessing the place of neurobiological explanations in accounts of a family member's addiction. Drug and Alcohol Review, 2016, 35, 461-469.	2.1	9
617	Adolescent Predictors of a Typology of DSM-5 Alcohol Use Disorder Symptoms in Young Adults Derived by Latent Class Analysis Using Data From an Australian Cohort Study. Journal of Studies on Alcohol and Drugs, 2016, 77, 757-765.	1.0	9
618	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. Pain Medicine, 2019, 20, 758-769.	1.9	9
619	Support for the psychosocial, disease and brain disease models of addiction: A survey of treatment providers' attitudes in Australia, the UK, and U.S Journal of Substance Abuse Treatment, 2020, 115, 108033.	2.8	9
620	Could vaping help lower smoking rates in Australia?. Drug and Alcohol Review, 2020, 39, 415-418.	2.1	9
621	Personal Correlates of Support for Medical and Recreational Cannabis Legalization in Australia. Frontiers in Psychiatry, 2021, 12, 551661.	2.6	9
622	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non ancer pain: A fiveâ€year prospective cohort study. British Journal of Clinical Pharmacology, 2021, 87, 3092-3104.	2.4	9
623	Advocates need to show compulsory treatment of opioid dependence is effective, safe and ethical. Bulletin of the World Health Organization, 2013, 91, 146-146.	3.3	9
624	Perceived access to cannabis and ease of purchasing cannabis in retail stores in Canada immediately before and one year after legalization. American Journal of Drug and Alcohol Abuse, 2022, 48, 195-205.	2.1	9
625	Issues in the assessment of outcome in depressive illness in the elderly. International Journal of Geriatric Psychiatry, 1991, 6, 269-277.	2.7	8
626	Jurisdictional trends in opioid overdose deaths, 1988-96. Australian and New Zealand Journal of Public Health, 1998, 22, 802-807.	1.8	8
627	Another mirror shattered? Tobacco industry involvement suspected in a book which claims that nicotine is not addictive. Addiction, 2002, 97, 1-5.	3.3	8
628	Heroin addiction and the capacity for consent: a reply to charland. Addiction, 2003, 98, 1775-1776.	3.3	8
629	The policy and ethical implications of genetic research on attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry, 2004, 38, 10-19.	2.3	8
630	The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 2005, 5, 84.	2.9	8

#	Article	IF	CITATIONS
631	Assessing the impact of prescribed medicines on health outcomes. Australia and New Zealand Health Policy, 2007, 4, 1.	2.2	8
632	Psychoactive drugs of misuse: rationalising the irrational. Lancet, The, 2007, 369, 972.	13.7	8
633	Professional and personal attitudes of researchers in ageing towards life extension. Biogerontology, 2009, 10, 73-81.	3.9	8
634	Anticipating the antiâ€ageing pill. EMBO Reports, 2009, 10, 108-113.	4.5	8
635	Anticipating the use of life extension technologies. EMBO Reports, 2010, 11, 334-338.	4.5	8
636	National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. Australasian Psychiatry, 2013, 21, 442-445.	0.7	8
637	Technical Note: On modelling thermo-chemical degradation of poly(lactic acid). Polymer Degradation and Stability, 2016, 134, 19-21.	5.8	8
638	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Australian Health Review, 2016, 40, 490.	1.1	8
639	Has Marijuana Legalization Increased Marijuana Use Among US Youth?. JAMA Pediatrics, 2017, 171, 116.	6.2	8
640	Alcohol advertisers may be using social media to encourage parents to drink during <scp>COVID</scp> â€19. Medical Journal of Australia, 2020, 213, 188.	1.7	8
641	Generational trends in US opioid-overdose deaths. Nature Medicine, 2020, 26, 651-652.	30.7	8
642	Age–period–cohort analysis of trends in tobacco smoking, cannabis use, and their coâ€use in the Australian population. Addiction, 2022, 117, 2730-2735.	3.3	8
643	Psychological Approaches to the Evaluation of Chronic Pain Patients. Australian and New Zealand Journal of Psychiatry, 1982, 16, 3-9.	2.3	7
644	The Australian Debate about the Legalization of Heroin and other Illicit Drugs, 1988–1991. Journal of Drug Issues, 1992, 22, 563-577.	1.2	7
645	Illicit amphetamine use as a public health problem in Australia. Medical Journal of Australia, 1993, 159, 643-644.	1.7	7
646	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 164, 508-508.	1.7	7
647	Breaking the deadlock over an Australian trial of injectable opioid maintenance. Medical Journal of Australia, 2002, 176, 72-73.	1.7	7
648	Genetic screening for susceptibility to depression: can we and should we?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 73-80.	2.3	7

#	Article	IF	CITATIONS
649	Minimising research censorship by government funders. International Journal of Drug Policy, 2006, 17, 240-241.	3.3	7
650	Cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 119-128.	1.4	7
651	Explaining the convergence of male and female smoking prevalence in Australia. Addiction, 2008, 103, 487-495.	3.3	7
652	A cautionary bibliometric tale of two cities. Scientometrics, 2010, 84, 317-320.	3.0	7
653	How can we reduce alcoholâ€related road crash deaths among young Australians?. Medical Journal of Australia, 2010, 192, 464-466.	1.7	7
654	Driving while under the influence of cannabis. BMJ: British Medical Journal, 2012, 344, e595-e595.	2.3	7
655	The perceived health risks of cannabis use in an Australian household survey. Drug and Alcohol Review, 2012, 31, 809-812.	2.1	7
656	Ethical implications of research on craving. Addictive Behaviors, 2013, 38, 1593-1599.	3.0	7
657	Patterns of tobacco smoking among illicit drug users in <scp>A</scp> ustralia 2001–2010. Drug and Alcohol Review, 2014, 33, 534-539.	2.1	7
658	Should Australia reconsider its ban on the sale of electronic nicotine delivery systems?. Lancet Respiratory Medicine,the, 2014, 2, 602-604.	10.7	7
659	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. International Journal of Clinical Practice, 2015, 69, 1366-1376.	1.7	7
660	Do Neurobiological Understandings of Smoking Influence Quitting Self-Efficacy or Treatment Intentions?. Nicotine and Tobacco Research, 2018, 20, 827-835.	2.6	7
661	The need to exercise caution in accepting addiction as a reason for performing euthanasia. Addiction, 2018, 113, 1178-1180.	3.3	7
662	Can automated content analysis be used to assess and improve the use of evidence in mental health policy? A systematic review. Systematic Reviews, 2018, 7, 194.	5.3	7
663	Longitudinal patterns of amphetamine use from adolescence to adulthood: A latent class analysis of a 20-year prospective study of Australians. Drug and Alcohol Dependence, 2019, 194, 121-127.	3.2	7
664	Availability of substances for use in personal vaporisers on three online cryptomarkets. Drug and Alcohol Dependence, 2020, 217, 108254.	3.2	7
665	Does the gateway theory justify a ban on nicotine vaping in Australia?. International Journal of Drug Policy, 2020, 78, 102712.	3.3	7
666	The Misuse of the Precautionary Principle in Justifying Australia's Ban on the Sale of Nicotine Vaping Products. Nicotine and Tobacco Research, 2021, 23, 14-20.	2.6	7

#	Article	IF	CITATIONS
667	Association between the implementation of tobacco control policies and adolescent vaping in 44 lowerâ€middle, upperâ€middle, and highâ€income countries. Addiction, 2022, 117, 2296-2305.	3.3	7
668	Psychotropic Drug Prescribing in an Australian General Practice. Family Practice, 1984, 1, 106-112.	1.9	6
669	Alcohol-related problems among Aboriginal drinkers in the Kimberley region of Western Australia. Addiction, 1993, 88, 1091-1100.	3.3	6
670	Perfectionism in the therapeutic appraisal of methadone maintenance. Addiction, 1993, 88, 1181-1182.	3.3	6
671	Alcohol Use and Incarceration in a Police Lockup among Aboriginals in the Kimberley Region of Western Australia. Australian and New Zealand Journal of Criminology, 1994, 27, 57-73.	2.5	6
672	Geographical differences in risk-taking among Sydney methadone maintenance patients: a comparison of inner city and outer south western methadone maintenance patients. Drug and Alcohol Review, 1994, 13, 301-305.	2.1	6
673	Taking Darwin Seriously: More Than Telling Just So Stories. Addiction, 2002, 97, 472-473.	3.3	6
674	Swedish snus for tobacco harm reduction – Authors' reply. Lancet, The, 2007, 370, 1206-1207.	13.7	6
675	Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. Drug and Alcohol Review, 2008, 27, 160-164.	2.1	6
676	State of the Nation's Mental Health 2007. Australian and New Zealand Journal of Psychiatry, 2009, 43, 591-593.	2.3	6
677	Smokeless tobacco use in Australia. Drug and Alcohol Review, 2009, 28, 284-291.	2.1	6
678	Avoiding Selective Ethical Objections to Nudges. American Journal of Bioethics, 2012, 12, 12-14.	0.9	6
679	Anticipating possible policy uses of addiction neuroscience research. Drugs: Education, Prevention and Policy, 2013, 20, 249-257.	1.3	6
680	Constraints on Regulatory Options for Putatively Cognitive Enhancing Drugs. American Journal of Bioethics, 2013, 13, 35-37.	0.9	6
681	Collecting realâ€ŧime data from substance users raises unique legal and ethical issues: reply to <scp>K</scp> untsche & <scp>L</scp> abhart. Addiction, 2014, 109, 1760-1760.	3.3	6
682	Possible causes and consequences of reduced perceptions of the risks of using cannabis. Clinical Toxicology, 2015, 53, 141-142.	1.9	6
683	The brain disease model of addiction: challenging or reinforcing stigma?–Authors' reply. Lancet Psychiatry,the, 2015, 2, 292.	7.4	6
684	A critical analysis of Australia's ban on the sale of electronic nicotine delivery systems. Neuroethics, 2021, 14, 323-331.	2.8	6

#	Article	IF	CITATIONS
685	Nonâ€medical use of pharmaceutical opioids with and without other illicit substances in Australia: Prevalence and correlates. Drug and Alcohol Review, 2019, 38, 151-158.	2.1	6
686	The "gateway―effect of e-cigarettes may be explained by a genetic liability to risk-taking. PLoS Medicine, 2021, 18, e1003554.	8.4	6
687	The Age of Onset of Substance Use Disorders. , 2019, , 149-167.		6
688	Evidence-based treatment for drug misuse: bridging the gap between aspiration and achievement. Addiction, 1997, 92, 373-374.	3.3	6
689	The Case of William Chidley: A Study in Psychiatry, Morality and Lunacy Law. Australian and New Zealand Journal of Psychiatry, 1980, 14, 133-139.	2.3	5
690	Highs and lows. Lancet, The, 1997, 350, SIII1.	13.7	5
691	Is Ultra-Rapid Opioid Detoxification a Viable Option in the Treatment of Opioid Dependence?. CNS Drugs, 2000, 14, 251-255.	5.9	5
692	The psychotogenic effects of cannabis use: challenges in reducing residual uncertainties and communicating the risks. Addiction, 2004, 99, 511-512.	3.3	5
693	The prospects for tobacco harm reduction. International Journal of Drug Policy, 2005, 16, 139-142.	3.3	5
694	Community Attitudes to the Regulation of Life Extension. Annals of the New York Academy of Sciences, 2007, 1114, 288-299.	3.8	5
695	Five Genetic Variants Associated with Prostate Cancer. New England Journal of Medicine, 2008, 358, 2738-2741.	27.0	5
696	THE AGENT ORANGE CONTROVERSY IN AUSTRALIA: A CONTRIBUTION TO THE DEBATE*. Community Health Studies, 1985, 9, 109-119.	0.0	5
697	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. Addiction, 2010, 105, 1332-1333.	3.3	5
698	Deep Brain Stimulation in Parkinsonian Patients—Implications for Trialing DBS in Intractable Psychiatric Disorders. AJOB Neuroscience, 2011, 2, 14-15.	1.1	5
699	Begging Important Questions About Cognitive Enhancement, Again. American Journal of Bioethics, 2011, 11, 14-15.	0.9	5
700	IS DEEP BRAIN STIMULATION FOR ADDICTION AN ACCEPTABLE CRIME CONTROL MEASURE?. Addiction, 2012, 107, 1360-1360.	3.3	5
701	EXPLORING CONDITIONS UNDER WHICH IT MAY BE ETHICAL TO OFFER INCENTIVES TO ENCOURAGE DRUGâ€USING WOMEN TO USE LONGâ€ACTING FORMS OF CONTRACEPTION. Addiction, 2012, 107, 1049-1050). ^{3.3}	5
702	Error and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools?. Pain Medicine, 2013, 14, 982-987.	1.9	5

#	Article	IF	CITATIONS
703	Repeated Head Injuries in Australia's Collision Sports Highlight Ethical and Evidential Gaps in Concussion Management Policies. Neuroethics, 2015, 8, 39-45.	2.8	5
704	Value for money in reducing opioid-related deaths. Lancet Public Health, The, 2017, 2, e124-e125.	10.0	5
705	The Indian Hemp Drugs Commission 1893–1894. Addiction, 2019, 114, 1679-1682.	3.3	5
706	New Zealand's failed cannabis legalization referendum – implications for cannabis policy reform. The Lancet Regional Health - Western Pacific, 2021, 7, 100080.	2.9	5
707	The evolution of population policy in Viet Nam. Asia-Pacific Population Journal, 2012, 27, 41-56.	0.5	5
708	Prevalence and correlates of cannabis use for medicinal reasons – An Australian cross-sectional study. Addictive Behaviors Reports, 2022, 15, 100436.	1.9	5
709	Making research more relevant to practice. Drug and Alcohol Review, 1995, 14, 149-150.	2.1	4
710	The Policy Implications of Cannabis Dependence. , 2001, , 315-340.		4
711	Addiction, ethics and scientific freedom. Addiction, 2003, 98, 873-874.	3.3	4
712	CANNABIS ABUSE AND DEPENDENCE. , 2008, , 117-148.		4
713	Challenges in reducing cannabisâ€related harm in Australia. Drug and Alcohol Review, 2009, 28, 110-116.	2.1	4
714	The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia 2000 to 2006. Australian and New Zealand Journal of Public Health, 2010, 34, 315-319.	1.8	4
715	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4
716	SCIENCE, SAFETY AND COSTS MAKE DEEP BRAIN STIMULATION FOR ADDICTION A LOW PRIORITY: A REPLY TO VORSPAN <i>ET AL</i> . (2011) AND KUHN <i>ET AL</i> . (2011). Addiction, 2011, 106, 1537-1538.	3.3	4
717	Indirect evidence of the contribution of prenatal sex selection practices to the high sex ratio at birth in Vietnam. Journal of Population Research, 2011, 28, 293-299.	1.1	4
718	Dealing with Ennui: To What Extent Is "Cognitive Enhancement―a Form of Self-Medication for Symptoms of Depression?. AJOB Neuroscience, 2013, 4, 17-17.	1.1	4
719	<scp>R</scp> obin <scp>R</scp> oom and cannabis policy: Dangerous comparisons. Drug and Alcohol Review, 2014, 33, 612-616.	2.1	4
720	Cannabis use and cannabis use disorders. Lancet Psychiatry,the, 2016, 3, 911-912.	7.4	4

#	Article	IF	CITATIONS
721	Assessing the place of nicotine vaporisers in tobacco control. Tobacco Control, 2016, 25, e1-e2.	3.2	4
722	Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. Lancet Psychiatry,the, 2017, 4, 265-266.	7.4	4
723	A prospectus for ethical analysis of ageing individuals' responsibility to prevent cognitive decline. Bioethics, 2017, 31, 657-665.	1.4	4
724	Smoking and finances: baseline characteristics of low income daily smokers in the FISCALS cohort. International Journal for Equity in Health, 2017, 16, 157.	3.5	4
725	Implications of treatment providers' varying conceptions of the disease model of addiction: A response. Drug and Alcohol Review, 2018, 37, 729-730.	2.1	4
726	Amphetamine use in the fourth decade of life: Social profiles from a populationâ€based Australian cohort. Drug and Alcohol Review, 2018, 37, 743-751.	2.1	4
727	Reducing the risks of distortion in cannabis research. Addiction, 2020, 115, 799-801.	3.3	4
728	A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. Drug and Alcohol Review, 2020, 39, 737-742.	2.1	4
729	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
730	Epidemiology of Substance Use Internationally. Advances in Prevention Science, 2019, , 19-36.	0.3	4
731	Antidepressant prescribing and suicide: Authors' reply. BMJ: British Medical Journal, 2003, 327, 289-289.	2.3	4
732	Did the underâ€reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?. Addiction, 2022, 117, 1787-1793.	3.3	4
733	State-Level Prevalence and Associates of Opioid Dependence in the USA. International Journal of Environmental Research and Public Health, 2022, 19, 3825.	2.6	4
734	Communication to the editor. Journal of Psychosomatic Research, 1982, 26, 99-100.	2.6	3
735	DISEASE COSTS AND THE ALLOCATION OF HEALTH RESOURCES. Bioethics, 1987, 1, 211-225.	1.4	3
736	Alcohol and recreational drug use by HIV-seropositive homosexual men. Drug and Alcohol Review, 1992, 11, 355-362.	2.1	3
737	Recent developments in the study of behaviour phenotypes. Journal of Intellectual & Developmental Disability, 1994, 19, 275-279.	0.3	3
738	Harm reduction as a focus for research. Drug and Alcohol Review, 1996, 15, 5-6.	2.1	3

#	Article	IF	CITATIONS
739	Cohort trends in youth suicide in Australia 1964-1997. Australian and New Zealand Journal of Psychiatry, 2000, 34, 408-412.	2.3	3
740	The Adverse Health and Psychological Consequences of Cannabis Dependence. , 2001, , 106-128.		3
741	MAPPING THE CONSEQUENCES OF AN UNANTICIPATED DRUG SUPPLY CHANGE OF UNCERTAIN ORIGINS: RESPONSE TO THE COMMENTARIES. Addiction, 2005, 100, 930-932.	3.3	3
742	UK classification of cannabis: is a change needed and why?. Lancet, The, 2007, 370, 1541.	13.7	3
743	Should We Recriminalize Cannabis Use? The Case against. Canadian Journal of Psychiatry, 2008, 53, 793-794.	1.9	3
744	A renewed call for action on alcohol policy. Addiction, 2010, 105, 767-768.	3.3	3
745	Listening to public concerns about human life extension. EMBO Reports, 2010, 11, 735-737.	4.5	3
746	BEWARE OF ALLOWING THE IDEAL TO BE THE ENEMY OF THE GOOD. Addiction, 2011, 106, 1555-1556.	3.3	3
747	Addiction May Not Be a Compulsive Brain Disease, But It Is More Than Purposeful Medication of Untreated Psychiatric Disorders. AJOB Neuroscience, 2012, 3, 54-55.	1.1	3
748	Afghanistan has a sizeable problem with opioid use. The Lancet Global Health, 2014, 2, e557-e558.	6.3	3
749	Response to <scp>H</scp> ser <i>et al</i> . (2014): The necessity for more and better data on the global epidemiology of opioid dependence. Addiction, 2014, 109, 1335-1337.	3.3	3
750	Commentary on Ogeil et al . (2016): Explaining increased alcoholâ€related harm and stable per capita consumption in Australia. Addiction, 2016, 111, 635-636.	3.3	3
751	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. International Journal of Drug Policy, 2019, 73, 96-99.	3.3	3
752	Vaping Nicotine Is Far Less Harmful Than Smoking Tobacco. Chest, 2020, 158, 835-836.	0.8	3
753	Emerging Neurobiological Treatments of Addiction. , 2012, , 95-113.		3
754	Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction, 1997, 92, 697-706.	3.3	3
755	Is there a role for contact tracing in preventing HIV transmission among injecting drug users?. Addiction, 1996, 91, 917-919.	3.3	3
756	Harm Minimization in a Prohibition Context—australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	3

#	Article	IF	CITATIONS
757	Is smoking reduction and cessation associated with increased e-cigarette use? Findings from a nationally representative sample of adult smokers in Australia. Addictive Behaviors, 2022, 127, 107217.	3.0	3
758	Efficacy of smokeless tobacco for smoking cessation: a systematic review and meta-analysis. Tobacco Control, 2023, 32, 757-768.	3.2	3
759	The iCannToolkit: a tool to embrace measurement of medicinal and nonâ€medicinal cannabis use across licit, illicit and crossâ€cultural settings. Addiction, 2022, , .	3.3	3
760	Changes in patterns of youth multiple tobacco and/or e-cigarette product use in the US between 2014 and 2020: a multiple-group latent class analysis. Tobacco Control, 2024, 33, 21-29.	3.2	3
761	A summary of recommendations for the management of opioid dependence: the quality assurance in the treatment of drug dependence project*. Drug and Alcohol Review, 1994, 13, 319-326.	2.1	2
762	Changes in the characteristics of clients admitted to an Australian therapeutic community, "The Butteryâ€; 1980-92. Drug and Alcohol Review, 1995, 14, 125-129.	2.1	2
763	Getting the Cannabis Withdrawal Question into Proper Perspective: Comments on Smith. Addiction, 2002, 97, 754-754.	3.3	2
764	Persons and Personification. American Journal of Bioethics, 2007, 7, 57-58.	0.9	2
765	What would evidence-informed drug policies look like?. Addiction, 2010, 105, 1135-1136.	3.3	2
766	Begging the Question: Presupposing That TMS Can Be Shown to Enhance Eyewitness Testimony. AJOB Neuroscience, 2010, 1, 34-35.	1.1	2
767	Drug trafficking: Time to abolish the death penalty. Journal of Substance Use, 2011, 16, 259-262.	0.7	2
768	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. Addiction, 2011, 106, 1192-1193.	3.3	2
769	In the Face of Uncertainty About the Risks of Low-Level Drinking, Abstinence Is Prudent, Not Misogynistic, Advice. American Journal of Bioethics, 2011, 11, 66-67.	0.9	2
770	Commentary on <scp>K</scp> elty & <scp>H</scp> ulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	3.3	2
771	STIMULATING DEBATE IN THE FIELD OF ADDICTION. Addiction, 2012, 107, 253-253.	3.3	2
772	Managing Suicide Risk in Experimental Treatments of Treatment-Resistant Depression. AJOB Neuroscience, 2013, 4, 38-39.	1.1	2
773	Did the elimination of lead from petrol reduce crime in the USA in the 1990s?. F1000Research, 2013, 2, 156.	1.6	2
774	Alienation and Authenticity in Parkinson's Disease and Its Treatment. AJOB Neuroscience, 2014, 5, 54-56.	1.1	2

#	Article	IF	CITATIONS
775	Nuances in the ethical regulation of electronic nicotine delivery systems. Addiction, 2015, 110, 1074-1075.	3.3	2
776	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
777	Reducing alcoholâ€related violence and other harm in Australia. Medical Journal of Australia, 2017, 206, 111-112.	1.7	2
778	Formulating more consistent public health policies towards cannabis and tobacco. Addiction, 2018, 113, 608-609.	3.3	2
779	â€~Ice Rushes', Data Shadows and Methylamphetamine Use in Rural Towns: Wastewater Analysis. Current Issues in Criminal Justice, 2018, 29, 195-208.	1.4	2
780	The need for more consistent evidential standards in cannabis policy evaluations. Addiction, 2018, 113, 1553-1554.	3.3	2
781	The Age of Onset of Alcohol Use Disorders. , 2019, , 169-182.		2
782	Capacity, control and responsibility in Parkinson's disease patients with impulse control disorders: Views of neurological and psychiatric experts. International Journal of Law and Psychiatry, 2019, 65, 101343.	0.9	2
783	Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?. Developmental Medicine and Child Neurology, 2020, 62, 1007-1007.	2.1	2
784	Road Safety Risks of Cannabis Use: Sales Need to Fund Research. American Journal of Public Health, 2020, 110, 265-266.	2.7	2
785	Adolescent cannabis use disorders. , 2020, , 111-135.		2
786	Attitudes towards a hypothetical â€ [~] clean nicotine' product and harm reduction among smokers. International Journal of Drug Policy, 2021, 88, 103020.	3.3	2
787	Reefer Madness: an undeserved classic movie. Addiction, 2021, 116, 963-969.	3.3	2
788	Drug Legalization is Not a Masterstroke for Addressing Racial Inequality. American Journal of Bioethics, 2021, 21, 44-46.	0.9	2
789	Was New Zealand's referendum to legalise cannabis premature?. Drug and Alcohol Review, 2021, 40, 882-883.	2.1	2
790	What can we learn from the history of research on psychedelic drugs in the addictions?. Addiction, 2021, 116, 2936-2938.	3.3	2
791	Reactions on Twitter towards Australia's proposed import restriction on nicotine vaping products: a thematic analysis. Australian and New Zealand Journal of Public Health, 2021, 45, 543-545.	1.8	2
792	Age-related trends in cannabis use in Australia. Findings from a series of large nationally representative surveys. Addictive Behaviors, 2021, 123, 107059.	3.0	2

#	Article	IF	CITATIONS
793	Methadone maintenance treatment. BMJ: British Medical Journal, 1995, 310, 1408-1408.	2.3	2
794	Property Crime and Income Generation by Heroin Users. Australian and New Zealand Journal of Criminology, 2002, 35, 187-202.	2.5	2
795	Alcohol tax reform: now is the time. Medical Journal of Australia, 2011, 195, 660-660.	1.7	2
796	Introduction: What is Addiction Neuroethics and Why Does it Matter?. , 2012, , xvii-xxv.		2
797	The injecting and sexual behaviour of intravenous drug users in Sydney. Medical Journal of Australia, 1990, 152, 446-446.	1.7	2
798	The Limitations of Multivariate Statistical Methods in the Mensuration of Human Misery. Australian and New Zealand Journal of Psychiatry, 1989, 23, 503-511.	2.3	1
799	Methadone maintenance treatment in prisons: The new South Wales experience. Psychiatry, Psychology and Law, 1994, 1, 33-44.	1.2	1
800	Variations in Prohibition: Harm Minimisation and Drug Wars in Australia and the United States. Australian and New Zealand Journal of Criminology, 1995, 28, 74-77.	2.5	1
801	Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-92: II. Alcohol problems. Drug and Alcohol Review, 1996, 15, 133-136.	2.1	1
802	The Decline in Alcohol Disorders with Age: Causes and Implications. Australasian Journal on Ageing, 1998, 17, 158-159.	0.9	1
803	No switching off the camera: howAddictionwill respond to infringements of ethical publishing expectation. Addiction, 2001, 96, 1391-1392.	3.3	1
804	In reply: Separating politics and scientific research on heroin prescription. Medical Journal of Australia, 2002, 176, 450-450.	1.7	1
805	Educating government officials about the health risks of cannabis. Journal of Policy Analysis and Management, 2002, 21, 121.	1.4	1
806	RETROSPECTIONS OF A RECOVERING DRUG RESEARCHER. Addiction, 2004, 99, 153-154.	3.3	1
807	Reply to Wodak. Addiction, 2004, 99, 1064-1064.	3.3	1
808	New Treatments for Addiction: Behavioural, Ethical, Legal and Social Questions. Addiction, 2004, 99, 1481-1481.	3.3	1
809	CANADIAN HEROIN SUPPLY AND THE AUSTRALIAN â€~HEROIN SHORTAGE'. Addiction, 2006, 101, 1667-1668.	. 3.3	1
810	The regulatory challenges in engineering a safer tipple. Journal of Psychopharmacology, 2006, 20, 321-322.	4.0	1

#	Article	IF	CITATIONS
811	Australian heroin seizures and the causes of the 2001 heroin shortage. International Journal of Drug Policy, 2008, 19, 293-294.	3.3	1
812	Drug use and drug dependence. , 0, , 230-249.		1
813	Obstacles to a Regulated Cannabis Market. Canadian Journal of Psychiatry, 2008, 53, 798-798.	1.9	1
814	Clashes between the government and its expert advisers. BMJ: British Medical Journal, 2009, 339, b4662-b4662.	2.3	1
815	Mapping Community Concerns About Radical Extensions of Human Life Expectancy. American Journal of Bioethics, 2009, 9, W4-W5.	0.9	1
816	Does a lack of specificity rule out a causal relationship between cannabis use and schizophrenia?. Addiction Research and Theory, 2010, 18, 606-608.	1.9	1
817	Beyond the Right to Injectable Heroin. AJOB Neuroscience, 2010, 1, 48-49.	1.1	1
818	Democratising assessment of researchers' track records: a simple proposal. Medical Journal of Australia, 2011, 195, 147-148.	1.7	1
819	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
820	<i>Addiction</i> 's priorities when evaluating submissions. Addiction, 2011, 106, 463-465.	3.3	1
821	UNTESTED ASSUMPTIONS ABOUT PUTATIVE NEUROENHANCEMENT. Addiction, 2011, 106, 1190-1191.	3.3	1
822	The implications of genetic research on alcohol dependence for prevention and treatment. , 0, , 16-30.		1
823	Is the nonâ€medical use of prescription stimulants a problem in Australia?. Medical Journal of Australia, 2012, 197, 145-145.	1.7	1
824	British cannabis policy: an enduring and uneasy compromise. Lancet, The, 2013, 381, 1351.	13.7	1
825	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
826	<i>Addiction</i> editors respond to Mr Leverton. Addiction, 2014, 109, 1209-1211.	3.3	1
827	Getting to grips with the cannabis problem: the evolving contributions and impact of Griffith Edwards. Addiction, 2015, 110, 36-39.	3.3	1
828	Estimating the number of regular and dependent methamphetamine users in Australia, 2002–2014. Medical Journal of Australia, 2016, 205, 426-426.	1.7	1

#	Article	IF	CITATIONS
829	Commentary on Imtiaz et al . (2016): The burden of disease attributable to cannabis—implications for policy. Addiction, 2016, 111, 663-664.	3.3	1
830	Mental disorders in offspring of parents who have been homeless. Lancet Public Health, The, 2017, 2, e530-e531.	10.0	1
831	Fischer et al. Respond. American Journal of Public Health, 2017, 107, e26-e27.	2.7	1
832	International Aspects of Cannabis Use and Misuse: the Australian Perspective. , 2017, , 101-109.		1
833	Ethical Guidelines for Genetic Research on Alcohol Addiction and Its Applications. Kennedy Institute of Ethics Journal, 2018, 28, 1-22.	0.5	1
834	Cannabis use and non-cancer chronic pain – Authors' reply. Lancet Public Health, The, 2018, 3, e469.	10.0	1
835	The challenges in providing safe, effective, affordable cannabisâ€based medicines for unapproved indications. Medical Journal of Australia, 2018, 209, 209-210.	1.7	1
836	Reasons for ambivalence about accepting addiction as a reason for performing euthanasia. Addiction, 2018, 113, 1186-1187.	3.3	1
837	Prisoners and risk of injury after release. Lancet Public Health, The, 2018, 3, e209-e210.	10.0	1
838	Commentary on Burgard et al . (2019): Wastewater based estimates of the size of illicit markets for psychoactive drugs. Addiction, 2019, 114, 1591-1592.	3.3	1
839	How many more young Australians say that they would use cannabis if it were legal?. Drug and Alcohol Review, 2020, 39, 768-772.	2.1	1
840	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. Public Health in Practice, 2020, 1, 100046.	1.5	1
841	Response to Chapman and Daube. Drug and Alcohol Review, 2020, 39, 422-423.	2.1	1
842	Disease, wellness, and addiction: AÂglobal perspective. , 2020, , 211-224.		1
843	The EVALI outbreak makes a strong case for better regulation of all vaporizer products. Addiction, 2021, 116, 999-999.	3.3	1
844	Aldous Huxley's Doors of Perception. Addiction, 2021, , .	3.3	1
845	Ethical and policy issues in the translation of genetic and neuroscience research on addiction. , 2007, , 439-457.		1
846	Population Approaches to Alcohol, Tobacco and Drugs. , 2012, , 247-260.		1

#	Article	IF	CITATIONS
847	Addictions. , 0, , .		1
848	The recent Australian debate about the prohibition on cannabis use. Addiction, 1997, 92, 1109-1116.	3.3	1
849	The distribution of naloxone to heroin users. Addiction, 1997, 92, 1195-1200.	3.3	1
850	Ethical Issues in the Neuroprediction of Addiction Risk and Treatment Response. , 2015, , 1025-1044.		1
851	What Is Addiction Neuroethics?. , 2015, , 995-998.		1
852	The Policy and Ethical Implications of Genetic Research on Attention Deficit Hyperactivity Disorder. Australian and New Zealand Journal of Psychiatry, 2004, 38, 10-19.	2.3	1
853	An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population. Addictive Behaviors, 2022, 127, 107216.	3.0	1
854	Neither the "Devil's Lettuce―nor a "Miracle Cure:―The Use of Medical Cannabis in the Care of Children and Youth. Neuroethics, 2022, 15, 1.	2.8	1
855	Drug Addiction, Society and Ethics. , 0, , 639-645.		1
856	Commentary on Beard <i>et al</i> .: Using survey data to test the hypothesis that eâ€cigarettes are a gateway to cigarette smoking in youth. Addiction, 2022, , .	3.3	1
857	The iCannTookit: A consensusâ€based, flexible framework for measuring contemporary cannabis use. Addiction, 0, , .	3.3	1
858	Schizophrenia secondary to cannabis use. , 0, , 169-178.		0
859	Behaviour Completion Mechanisms, Anxiety and Agoraphobia. Australian and New Zealand Journal of Psychiatry, 1989, 23, 373-378.	2.3	0
860	Benzodiazepine prescribing and injecting drug users. Medical Journal of Australia, 1992, 157, 573-574.	1.7	0
861	Value for money in addiction services. Addiction, 1994, 89, 920-921.	3.3	0
862	Steering a course between the Charybdis of credulity and the Scylla of scepticism. Addiction, 1996, 91, 770-773.	3.3	0
863	Statistical questions. Addiction, 1996, 91, 1808-1809.	3.3	0

The association between cannabis use and depression: a review of the evidence. , 2004, , 54-74.

0

#	Article	IF	CITATIONS
865	Ethical Considerations for Drug Abuse Epidemiologic Research. , 2005, , 145-157.		0
866	The evidence base for registration and reimbursement of new pharmaceuticals in cancer treatment: Surrogate and real health outcomes. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 119-121.	1.1	0
867	ETHICAL EYE: DRUG ADDICTION. Addiction, 2006, 101, 460-461.	3.3	Ο
868	Cannabis-Induced Psychosis among Aboriginal People in the Northwest Territories. Canadian Journal of Psychiatry, 2007, 52, 475-476.	1.9	0
869	Biomedicalization of Alcohol Studies: Ideological Shifts and Institutional Challenges. Addiction, 2007, 102, 494-495.	3.3	0
870	Drugs and the Future: Brain Science, Addiction and Society. Addiction, 2007, 102, 1170-1170.	3.3	0
871	Marketing Health: Smoking and the Discourse of Public Health in Britain, 1945-2000. Addiction, 2008, 103, 515-516.	3.3	0
872	Response to Brewer. Drug and Alcohol Review, 2008, 27, 448-449.	2.1	0
873	Drug Trafficking: Time to Abolish the Death Penalty. Journal of Groups in Addiction and Recovery, 2009, 4, 322-326.	0.4	Ο
874	Policy forum. Drugs and Alcohol Today, 2009, 9, 11-14.	0.7	0
875	Drug Trafficking: Time to Abolish the Death Penalty. International Journal of Mental Health and Addiction, 2010, 8, 616-619.	7.4	0
876	Smokeless tobacco products: Unrecognised regulatory and policy opportunities. Drug and Alcohol Review, 2010, 29, 119-120.	2.1	0
877	Adverse health effects of non-medical cannabis use – Authors' reply. Lancet, The, 2010, 375, 197.	13.7	Ο
878	Research methods and statistical techniques in addiction. Addiction, 2012, 107, 1724-1725.	3.3	0
879	Response to commentaries: Slowing down the rush to translation in personal genomics. Addiction, 2012, 107, 2081-2081.	3.3	Ο
880	The public health implications of genetic research on addiction. , 0, , 155-173.		0
881	Griffith Edwards. BMJ, The, 2012, 345, e7234-e7234.	6.0	Ο
882	Response to <scp>R</scp> eitan. Addiction, 2013, 108, 650-651.	3.3	0

#	Article	IF	CITATIONS
883	Smoking and mental health in young women – challenges in interpretation: a reply. Psychological Medicine, 2013, 43, 445-447.	4.5	0
884	Justice and Equity in Trials of Deep Brain Stimulation for the Treatment of Addiction and Overeating. AJOB Neuroscience, 2013, 4, 54-56.	1.1	0
885	Drug Decriminalization and Legalization. , 2013, , 689-696.		0
886	Illicit Drugs. , 2014, , .		0
887	Ethical, Social and Clinical Challenges in using Deep Brain Stimulation to Treat Addiction and Other Impulsive and Compulsive Disorders. Jahrbuch Für Wissenschaft Und Ethik, 2015, 19, 163-188.	0.2	0
888	Are addicted individuals responsible for their behaviour?. , 0, , 146-167.		0
889	An Ethical Reevaluation: Where Are the Voices of Those With Anorexia Nervosa and Their Families?. AJOB Neuroscience, 2015, 6, 73-74.	1.1	0
890	Vote of thanks to Professor Tom Babor. Addiction, 2015, 110, 1060-1060.	3.3	0
891	Lucas Richert,Conservatism, Consumer Choice and the Food and Drug Administration during the Reagan Era. Social History of Medicine, 2016, 29, 202-203.	0.2	0
892	Substance Use Terminology. JAMA - Journal of the American Medical Association, 2017, 317, 769.	7.4	0
893	Regulating eâ€cigarettes in Australia: implications for tobacco use by young people. Medical Journal of Australia, 2018, 208, 415-415.	1.7	0
894	Imperfect international treaties interpreted flexibly are likely to be better than no treaties. Addiction, 2018, 113, 1230-1230.	3.3	0
895	Finding acceptable ways to fund research on e igarettes. Addiction, 2019, 114, 375-376.	3.3	0
896	Cognitive research on addiction in a changing policy landscape. , 2020, , 321-329.		0
897	Addiction 's policy on publishing effectiveness studies of involuntary treatment of addiction and its variants. Addiction, 2020, 115, 1795-1796.	3.3	0
898	Short-Term Effects of State Legalization on Adolescent Cannabis Use May Not Predict Any Longer-Term Effects. American Journal of Public Health, 2020, 110, 1270-1271.	2.7	0
899	Cannabinoids for the treatment of mental disorders – Author's reply. Lancet Psychiatry,the, 2020, 7, 127-128.	7.4	0
900	Policyâ€based evidence on e•igarette, or vaping product, use–associated lung injury. Drug and Alcohol Review, 2020, 39, 426-427.	2.1	0

#	Article	IF	CITATIONS
901	Commentary on Shi & Liang (2020): Has cannabis legalization increased acute cannabisâ€related harms?. Addiction, 2020, 115, 1900-1901.	3.3	0
902	Easier patient access to medical cannabis carries risks as well as benefits. Journal of Psychopharmacology, 2021, 35, 1435-1436.	4.0	0
903	Response to Daube & Chapman. Addiction, 2021, 116, 2588-2589.	3.3	Ο
904	Australian policymakers do not have to choose between protecting youth and allowing smokers to use nicotine vaping products. Addiction, 2021, 116, 2257-2259.	3.3	0
905	Increased barbiturate deaths: an unintended consequence of increased publicity for methods of doâ€itâ€yourself euthanasia?. Addiction, 2021, 116, 3273-3275.	3.3	0
906	GewohnheitsmÃðŸiger Cannabiskonsum und Teilnahme am Straßenverkehr. , 2002, , 355-361.		0
907	A Cautious Case for Cannabis Depenalization. , 2006, , 91-112.		0
908	Technical, Ethical and Social Issues in the Bioprediction of Addiction Liability and Treatment Response. , 2012, , 115-135.		0
909	Ethical Issues in the Treatment ofÂDrugÂDependence. , 2013, , 611-620.		0
910	Addiction Neuroethics. , 2013, , 541-549.		0
911	Gateway Drug Use. , 2016, , 1-9.		0
912	Looking to the future: Clinical and policy implications of the brain disease model of addiction. , 2017, , .		0
913	Concussion, neuroethics, and sport: Policies of the past do not suffice for the future. , 2017, , .		0
914	Gateway Drug Use. , 2018, , 1530-1538.		0
915	The Agent Orange controversy. Medical Journal of Australia, 1987, 146, 453-454.	1.7	0
916	The Australian policy debate about human embryonic stem cell research. Health Law Review, 2003, 12, 27-33.	0.1	0